



STROKE GUIDELINES

of the Bern Stroke Network

S. Jung, T. Meinel

P. Bücke, D. Seiffge, B. Birner, T. Horvath, M. Heldner, U. Prange, B. Volbers, H. Sarikaya, S. Muth, A. Luczkiewicz, P. Correia, A. Humm, S. Renaud, R. Bühler, J. Gralla, J. Kaesmacher, H. Mattle, M. Bühlmann, A. Angelillo-Scherrer, D. Bervini, W. Z` Graggen, A. Raabe, M. Arnold, U. Fischer for the **Stroke-Team Bern**

CONTACT NUMBERS

Neurology

Senior Physician (24/7)
Stroke Unit Neurological Ward
Neuroreha triage

ICU Shift supervisor

Anaesthesia

NRAD Resident MRI
NRAD Resident CT
NRAD Senior Physician Angio Suite

Neurosurgery Assistant
Neurosurgery Senior Physician

General Radiology Technical
Assistant

ED

- Senior Physician Medicine
- Senior Physician Surge
- Shift Supervisor Nursing
- Triage

On-Call Doctor (Anesthesia,
Intensive Care, and Emergency
Medicine Department

Stroke Unit

Stroke Unit Assistant (7–16h)
Late shift (14–23h) Nursing care
ICU Shift supervisor

Weekend service – Neurology Ward

Resuscitation MET Team

NRAD MR tech (24/7)
NRAD CT tech (7–19h)
NRAD Angio tech
Emergency CT tech (24/7)

Cardiology on-call

Infectiology on-call

Clinical Chemistry Laboratory
Coagulation Laboratory
Hematology Laboratory

Supported by

CONTENTS



ACUTE THERAPY

Prehospital phase & triage.....	4-6
Indications and choice of therapy.....	10
Contraindications IVT.....	11
IVT dosage.....	12
IVT in case of recent DOAC intake.....	12
Monitoring during IVT.....	13
Antihypertensive medication.....	13
Stroke unit treatment.....	14
Mobilization.....	15
Daily Checklist Stroke Unit.....	15
Prevention of deep vein thrombosis.....	16
DD neurological deterioration.....	16
Thrombolysis associated hemorrhage.....	16
DD myocardial infarction DD stress cardiomyopathy.....	16
Malignant infarcts.....	17
Agitation/delirium.....	18
TIA and Minor Stroke.....	19



ETIOLOGY

Diagnostic workup.....	20-21
Cardioaortic Imaging & PFO-associated ischemic stroke.....	22-23
(A)symptomatic artery stenosis.....	24
Dissections.....	25
Primary angiitis of the CNS.....	26-30
Reversible cerebral vasoconstriction syndrome.....	31
Cerebral venous and sinus thrombosis.....	32
Therapeutic heparinization.....	32



PREVENTION

Secondary prevention.....	34
Secondary prevention in special situations.....	35
Covert cerebrovascular disease.....	36
Direct oral anticoagulants (DOAC).....	37
Risk factors and stratification.....	38
Arterial hypertension.....	39
Dyslipidemia.....	40
Diabetes mellitus.....	41
Diet.....	42
Body weight and smoking.....	43
Physical activity.....	43
Follow-ups.....	43



HEMORRHAGIC STROKE

Non traumatic intracerebral hemorrhage.....	44
Anticoagulation reversal for ICH.....	45
Diagnostic algorithm.....	46
Restarting oral anticoagulation after ICH.....	46
Microbleeds.....	47
Cerebral amyloid angiopathy.....	47-48
CAA associated inflammation.....	48
Atraumatic subarachnoid hemorrhage.....	49



LIFE AFTER STROKE

Monogenic cerebrovascular diseases.....	50
Life after stroke checklist.....	51



OTHER TOPICS, FIGURES & SCORES

Central retinal artery occlusion (CRAO).....	52
Fig. Scheme of functional systems.....	53
Fig. Brain supplying arteries.....	54-55
Fig. Vascular territories.....	56-57
Pictures for assessment of naming and spatial recognition.....	58-59
Reading samples.....	60
Neurovascular Board.....	61
CHA ₂ DS ₂ -VASc Score, Modified Rankin Skala.....	61
NIHSS.....	62-63
Visual acuity testing.....	64
Arterial access site complications.....	65
Simplified mRS.....	66
NIHSS.....	68

CONTACT INFORMATION AND PARTICIPATING CLINICS

Prof. Dr. med. S. Jung, Dept. Head Neurorehabilitation, Tel. +41 (0)31 632 78 32, simon.jung@insel.ch

Prof. Dr. med. M. Arnold, Head, Stroke Center, Tel. +41 (0)31 632 78 32, marcel.arnold@insel.ch

Prof. Dr. med. Thomas Meinel, Head Neuro Emergency, Tel +41 (0)31 632 91 86, thomas.meinel@insel.ch

Secretariat Stroke Centre: Tel. +41 (0)31 632 78 32, stroke@insel.ch

Apps by Stroke Center Bern



NeuroED

Apple

Android

Links to additional documents including pediatric stroke guidelines

www.strokecenter.ch

University of Bern, Department of Neurology

Prof. Dr. T. Meinel, Prof. M. Arnold, Dr. T. Horvath, Prof. D. Seiffge, Prof. M. Heldner, Prof. H. Sarikaya, PD Dr. P. Bücke, Dr. M. Oberholzer, Dr. M. Bühlmann, PD Dr. B. Volbers, Dr. M. Göldlin, Dr. A. Scutelnic, A. Cramatte, Prof. U. Fischer, Prof. S. Jung

University of Bern, Department of Diagnostic and Interventional Neuroradiology

Prof. J. Gralla, PD Dr. E. Piechowiak, PD Dr. T. Dobrocky, Prof. Dr. J. Kaesmacher, Dr. S. Pilgram-Pastor, Prof. R. Wiest, M. Mordasini

University of Bern, Department of Neurosurgery

Prof. A. Raabe, Prof. P. Schucht, Prof. Dr. D. Bervini, Prof. W. Z`Graggen, Dr. Petutschnigg

University of Bern, Department of Anesthesia and Pain Therapy

Prof. F. Stüber, Dr. F. Neff, Prof. T. Riva, Dr. M. Abbühl

University of Bern, Emergency Department

Dr. Beat Lehmann, Prof. Dr. Martin Müller

University of Bern, Department of Intensive Care

Prof. J. Schefold

University of Bern, Department of Cardiology

Prof. S. Windecker, Prof. H. Tanner, Prof. L. Roten, Prof. L. Räber, Prof. T. Reichlin, Prof. C. Gräni

University of Bern, Department of General Medicine

Prof. D. Aujeski, Dr. M. Perrig, Prof. N. Rodondi

University of Bern, Department of Hematology and Hematological Central Laboratory

Prof. A. Angelillo-Scherrer, Prof. J.A. Kremer Hovinga

University of Bern, Department of Rheumatology

PD Dr. L. Seitz, Dr. F. Lötscher

University of Bern, Department of Diabetology, Endocrinology, Nutrition Medicine and Metabolism

Prof. L. Bally

University of Bern, Department of Human Genetics

Prof. Dr. Dr. med. C. Zweier

Department of Ophtalmology

Dr. med. Chantal Dysli, PhD

Drawings by Anja Giger, may be freely distributed with appropriate source citation.

Eye chart: PD M. Abegg, S. Küng;

Many thanks for translation and corrections to Susan Kaplan

All information provided without guarantee.

This version 08/2026 replaces the guidelines from 01/2024.

Ambulance SOP

Case history	Diagnostics
- Symptom onset or last-seen-well time - Previous history/medication? - Relevant pre-existing condition/impairment? - Pacemaker/artificial heart valve? (MRI) - Phone number of next of kin or GP - For frail or multimorbid patients: previous condition? - Patient's wishes (resuscitation, interventions)?	- ABC scheme - Glucose - Temperature - GCS - RACE or G-FAST score
Triage	
See chapter on patient triage Early information transmitted to Stroke Centre/Unit to decide triage, fastest transportation Stroke Center Bern Patient admission: 031 632 4012	
Position	
→ Supine position – max. 30° if possible (when indicated due to other reasons higher positions are possible, e.g. if patient has respiratory problems)	
Therapy	
→ Venous line → Aim blood oxygen saturation > 92% → BP aim 120–220 mmHg syst, < 120 mmHg diast > 220 mmHg syst. or > 120 mmHg diast: lower carefully < 120 mmHg syst: 500 ml NaCl WARNING Do not administer aspirin, heparin or similar medication	

Patient triage

Symptom onset < 4.5 h	RACE score < 5 → admit to nearest Stroke Unit (if IVT can be initiated within 4.5 h) consider IVT and transport to stroke center in case of large vessel occlusion: ICA, Carotid T, M1, M2, BA, P1, A1 RACE Score ≥ 5 Distance to Stroke Center < 20 min longer than to Stroke Unit → admit directly to Stroke Center Distance to Stroke Center > 20 min longer than to Stroke Unit → admit to Stroke Unit, IVT if indicated and transport to Stroke Center in case of large vessel occlusion: ICA, Carotid T, M1, M2, BA, P1, A1
Symptom onset 4.5–24 h	→ admit to nearest Stroke Center
Symptom onset > 24 h	→ admit to nearest Stroke Unit or Stroke Center
Stroke Unit: availability of IVT, Stroke Center: availability of IVT + EVT IVT: intravenous thrombolysis, EVT: endovascular treatment ICA: internal carotid artery, BA: basilar artery, M1-2: middle cerebral artery, A1: anterior cerebral artery, P1: posterior cerebral artery	

Prehospital phase

RACE Score

	“Show me your teeth”					
	No palsy (symmetrical movement)					0
	Mild (slight asymmetric)					1
	Moderate to severe (complete asymmetry)					2
	“Extend your arms and hold them there” (supine 45°, otherwise 90°)					
	Normal to mild: arms held out > 10 sec					0
	Moderate: one or both arms held out < 10 sec					1
	Severe: unable to raise arm(s) against gravity					2
	“Extend your legs and hold them there” (30° in supine position)					
	Normal to mild: legs raised for > 5 sec					0
	Moderate: one or both legs raised for < 5 sec					1
	Severe: unable to raise leg(s) against gravity					2
	Gaze deviation					
	Absent					0
	Deviation of eyes or head					1
 If palsy is right-sided	“Close your eyes” + “Make a fist”					
	Normal, both commands followed					0
	Moderate: one command not followed					1
	Severe: neither of the commands followed					2
 If palsy is left-sided	“Whose arm is this?” + “Does your arm feel weak?”					
	Normal: recognizes arm, aware of impairment					0
	Asomatognosia or anosognosia					1
	Asomatognosia AND anosognosia					2
Perez de la Ossa Stroke 2014	Probability of large vessel occlusion depending on summed score					
	1	8%	4	34%	7	72%
	2	14%	5	47%	8	81%
	3	22%	6	61%	9	86%

Perez de la Ossa Stroke 2014

Swiss Stroke centres, Stroke Units & Rehab



In-hospital stroke

Alert: Senior Consultant Neurologist *5488/23581 (until 4 p.m.), then on-call Neurologist (*6009)

- Consultant Neurologist/Neurological Emergency Team immediately attends the patient (preferably in neuroimaging MRI or CT) if clear suspicion of stroke, otherwise on the ward first
- Blood pressure/pulse monitoring via monitors from the department on the relevant ward
- **Patient escorted and monitored (including MRI/CT scans, if necessary) by the physician and nursing staff on the respective ward** or anaesthesia (*8555), if necessary
- Preparation and administration of thrombolysis by the Neurology Team (Fellow/Consultant during the day, on-call at night/Neurology Night Physician 20974)
- **The responsible departmental physician is responsible for the patient until transfer to the Stroke Unit/Intensive Care**

Paediatric stroke

- Consultation with senior pediatric neurologist *8566 and pediatrics
- Always treated in the trauma bay
- Treatment decision interdisciplinary with neuropaediatrics
- Tenecteplase dose analogous to adult dose: 0.25 mg/kgKG (calculated by exact body weight)

Hospital phase

be	SAFE	STROKE PATH
F A S T	Registration	? Symptoms, symptom onset, last known well ? ABCDE, CCS, blood sugar, blood thinners ? Arrival time ? Previous reports: anticoagulation? Epilepsy? ? MR-incompatible material? ? Resuscitation/patient's wishes
	Acute care or trauma bay	Usually, acute care bay: Consultation with nurse if arrival is <10 minutes *8130 Trauma bay if unstable → inform Triage 23636
	Prenotification	MRI 26200, Neuro CT 28272 (07:00–19:00), Emergency CT 46201 Anaesthesia if thrombectomy is likely, or patient unstable *8555
	Drip & ship?	Mon–Fri 07:30–17:00: "Direct to Angio" (see SOP) 17:00–07:30: acute care bay, NIHSS, info to NRAD (23460), repeat MRI/CT if necessary
max 10'	Arrival in trauma bay or acute care bay	Repositioning, blood sample, temperature, pants (for incontinent or non-adequate patients) Monitoring NIHSS (don't lose any time!) ECG? Only if chest pain or clear indication
	Acute care nurse*7968	ACN from 7:10 a.m. to 11:00 p.m. — ALWAYS when evaluating for IVT/EVT* *1 ACN per shift for all patients; Lead nurse decides if it's possible Always with a backpack + accompanied by neuro resident in Neurology If not available: Anaesthesia if monitoring is indicated
	CT 28272 or MRI 26200 or ED CT 46201	ED CT: if NIHSS ≥ 7 and onset ≤ 4h "lysis window"; additionally call NRAD *5563 CT (NRAD or ED): if pacemaker, implant (page 9, caution in case of aphasia/dementia), altered consciousness/restlessness; vomiting MRI: especially in case of wake-up, onset ≥ 4h, TIA or atypical clinical presentation, pregnancy
	Imaging priority?	Priority 1 immediately IVT/EVT indication = debilitating, new deficit, Onset within <12 hours/ Priority 2 within 10 min Probably no indication for IVT/EVT but debilitating, new deficit Started 12–24 hours ago Priority 3 within 2h No functional deficit Onset > 24 hours ago
max 15'	Arrival CT/MR	MRI order, including safety questions via EPIC (Assistant Doctor, Neurology) → Help with repositioning Remove glasses and hearing aids at the latest when entering the stroke unit preparation area (MRI) (Team)
	Monitoring	Monitoring during MR O ₂ needed to keep Biox >92% BP sys > 165 or < 100 Pulse > 110 or < 50 Patient cannot ask for help him/herself Acute Care Nurse / Anaesthesia / Assistant Doctor in MRI if: Patient cannot ask for help by him/herself Patient agitated
	Physician presence	Obligatory in case of Priority 1+2: always Priority 3: if criteria for monitoring are fulfilled (exception O ₂ < 4l) Not required if DWI/SWI/TOF negative + no other indication for medical supervision; in the event of life-threatening conditions in other patients, anesthesia team may need to be called. Once the (procedure/monitoring) is ended → organize return by transport!
	Therapy decision	IVT conditions among others: BP <185/105, review contraindications beforehand, see page 11 EVT: Discuss immediately after the first images via extension 23484 with Senior Neurologist, EVT approved → see next page For conservative treatment/no stroke: organize return via transport service if stable; otherwise, the patient should be taken back to the neurology floor by Acute Care Nurse / Assistant Doctor Neuro / study staff
	IVT/EVT	IVT start in MRI/CT: Interrupt MRI after the native sequences once it is clear that IVT will be administered, the medication is ready, and there are no contraindications For EVT: Hand over the patient to the interventionalist + anaesthesia team in the NeuroAngio suite
	Stroke Unit /ICU	20854: Senior Doctor (OA) on the Stroke Unit during the day, or 43742 at night. *7770: Shift Leader in the Intensive Care Unit
	Arrival SU/ICU	ECG: monitor, and, if necessary, take the oxygen bottle back to the emergency dept. Refill the Acute Care Nurse's backpack

If 10 minutes after the patient's arrival there has still been no call to NRAD, then rad tech should call NRAD at 6009

Hospital phase II EVT

be SAFE

THROMBECTOMY PATH

FAST

max
30'

Registration	*Activate pre-alert *8555 → Notify anaesthesia definitively as soon as it is confirmed that a thrombectomy will be performed (otherwise, cancel the premonition)		
Transport to Neuroangio	Neurology resident, ED nurse, radiological technologist for MRI/CT NRAD		
Drip & ship?	Mo–Fr 07:30–17:00 "Direct to Angio" (see SOP) 17:00–07:30: ED bay → NIHSS → inform NRAD (23460), repeat MRI/CT if necessary		
Arrival Neuroangio	Latest time for 2nd peripheral line insertion. To be done by: neurology nursing staff (UKN), neurology assistant doctor (AA Neuro), or anaesthesia team (depending on availability) Handover from neurology to anaesthesia & neuroradiology: - Age, onset/LKW, NIHSS, IVT yes/no, antithrombotic therapy, comorbidities (especially cardiopulmonary), resuscitation status, special considerations - Usually general anaesthesia (intubation); if necessary, discuss monitored anaesthesia care (MAC) with interventionalist at extension 23484 - Post-interventional bed (typically Stroke Unit; if Unit is full or patient unstable, transfer to ICU - Contact number resident Neurology for transport after the intervention Airway assessment by anaesthesia: adjust time limits if airway is difficult		
Induction of general anaesthesia / MAC Preparation for EVT	Everyone in the room wears a surgical mask and cap <table border="0"> <tr> <td> Clin. anaesthesiological assessment - Prepare medicines and materials - Arterial catheter if time allows as last step - Induction (respect BP limits, see below) - Approval for intervention </td> <td> Neuroradiology - Positioning and pants - Uncovering intervention material - Femoral arterial catheter for BP monitoring if no arterial BP obtained by KAS </td> </tr> </table>	Clin. anaesthesiological assessment - Prepare medicines and materials - Arterial catheter if time allows as last step - Induction (respect BP limits, see below) - Approval for intervention	Neuroradiology - Positioning and pants - Uncovering intervention material - Femoral arterial catheter for BP monitoring if no arterial BP obtained by KAS
Clin. anaesthesiological assessment - Prepare medicines and materials - Arterial catheter if time allows as last step - Induction (respect BP limits, see below) - Approval for intervention	Neuroradiology - Positioning and pants - Uncovering intervention material - Femoral arterial catheter for BP monitoring if no arterial BP obtained by KAS		
Start intervention	Neuroradiology		
BP target at induction and start of the intervention	If initial syst > 180mmHg, lowering to 180 mmHg can be tolerated If initial syst 120–180 mmHg, a max drop of 20 mmHg can be tolerated If initial syst < 120mmHg, consider raising to 120–140 mmHg Even short drops in BP must be avoided		
Intervention	Under general anaesthesia, deep anaesthesia or relaxation, no coughing or movement of the patient After the intervention phone info. from interventionalist to on-call neurologist Neuro *6009: Final TIC? Stenting? Antithrombotic therapy? Complications? Early control image?		
BP limits over time	Update as per the interventionalist's instructions, depending on the course of the intervention		
Transport to Stroke Unit or Intensive Care	Inform the neurology resident as soon as transport is expected (23585, 23586 oder 20974) Anaesthesia and neurology resident to coordinate together		
Arrival Stroke Unit or ICU	- Transfer by Neurology and anaesthesia - Take monitor and oxygen cylinder back to ED if necessary		

MRI suitability

Jewellery and foreign materials should be removed by the nursing/neurology team in the cubicle

Glasses and hearing aids should be removed at the latest in the Stroke preparation area and a double-check by the MRI technician is required! (4-eyes principle)
Staff (including the neurology team and ACN) must work metal-free (no jewellery, belts, etc.).

All MRI-incompatible foreign materials (e.g., reflex hammer, phone, keys) should be placed in doctor's overall, which is then hung up outside the MRI room (hook near MRI entrance)

Check **"metal-free"** before entering MRI by the NRAD radiographer (MTRA)

Type	Suitability	Procedure
Jewellery not removable	Suitable if not removable	Inform MTRA
Joint prosthesis, osteosynthesis material Spondylodesis, bypass	Suitable	Inform MTRA
Stent, coil, clip	Suitable	Inform MTRA
Heart valves Ear tubes PFO/ASD closure Thoracoabdominal stents and vascular prostheses	Suitable	Inform MTRA
Pacemakers / ICDs Shunts, including shunt valves Pumps Stimulators Cochlear implants	No acute MRI! Type dependent NRAD MTRA performs evaluation in consultation with Rhythmology or Neurosurgery as per SOP	→ Surgical report with exact implant identification to be sent to NRAD along with registration Caution is needed with pacemaker lead identification, as these may also not be MRI-compatible Such clarifications usually take too much time (approx. 30–90 minutes)

If patient sedated, BiOx monitoring during imaging

Medication	Dose	Comments
Midazolam (Dormicum®)	1mg test dose Administered in 1mg increments Sedation effect typically with 1–5mg, maximum total dose 10mg, then consult Senior Physician Neuro/Anaesthesia	Antidote: flumazenil (Anexate®) 0.2mg over 15 seconds, then possibly additional doses every 60 seconds, maximum total dose 1mg
Propofol (Propofol®)	Only in presence of Anaesthesia	

Indications and choice of therapy

Vessel occlusion	Time & Imaging		
	< 4.5 h also treatment if no infarct core perfusion/ FLAIR mismatch can be detected	4.5 - 11 h	Wake up/ Unknown onset/ or >11h - 48h:
ICA, Carotid-T, M1, prox. M2	IVT (especially if up to 140 min after onset) and EVT	EVT usually independent of core/perfusion or core/clinical mismatch [#] , consider bridging IVT (for transfer patients) [#]	EVT depending on ASPECTS and including mismatch/ collaterals [@]
PT, A1, VA	IVT & consider EVT if large perfusion deficit (MANAGE-DISTAL?)	IVT if mismatch [#] , consider EVT preferably in trials	IVT if mismatch ^{was} , consider EVT preferably in trials
Dist. M2 (<1/3 MCA territory), M3/4, P2/3, A2/3/4	IVT, EVT only in trials	EVT/ i.a. thrombolytics only in trials	IVT if mismatch/ collaterals [#] & consider EVT if large perfusion deficit (preferably in trial)
BA	Bridging	EVT ^s	EVT depending on pcASPECTS and considering mismatch ^{@s}
No detectable vessel occlusion	IVT	IVT if Mismatch [#]	IVT if Mismatch [#]
Spinal Ischemia	IVT	Consider IVT up to 6h	



Presentation
NIHSS Score ≥ 4
or
NIHSS < 4 with relevant disabling deficit (e.g. aphasia, hemianopia, distal paresis)
or
Consider for persistent vascular occlusion with minor deficits and/or rapid clinical improvement

* Individual decision depending on infarct core-perfusion mismatch

Diffusion FLAIR mismatch (no or markedly incomplete FLAIR demarcation of the DWI lesion) or perfusion infarct core mismatch (up to approx. 70mL infarct core, mismatch ratio >1.2)

s If EVT is not technically possible, IVT can also be considered for large vessel occlusion beyond 4.5h in case of mismatch (see #)

@ If (pc)ASPECTS >5 always EVT regardless of perfusion, if (pc)ASPECTS <6 relative indication depending on patient's wishes with overall poor prognosis (age, pre-mRS, comorbidity). In the presence of collaterals in multiphase CTA rather proactive.

IVT: intravenous thrombolysis; EVT: endovascular treatment; BA: basilar a., M1-4: middle cerebral a., A1-2: anterior cerebral a., VA: vertebral a., PT-2: posterior cerebral a.

Contraindications

IVT	EVT	
Relative	Absolute	Septic embolization, endocarditis, encephalitis, pancreatitis
		Acute intracranial hemorrhage (MRI/CT) or cerebral hemorrhage within the last 3 months
		INR > 1.7 with Marcoumar; with DOACs – especially Rivaroxaban – can also be higher if there are no other indications of coagulopathy
		Surgery at non-compressible sites within the past 10 days
		Manifest CAA (cerebral hemorrhage, TFNE, cognitive decline) with superficial siderosis or more than 10 lobar microbleeds
		Severe trauma (within the last 14 days) or severe traumatic brain injury (within the last 14 days)
	Relative	Intraparenchymal hemorrhage within the past 3 months
		Delivery within the past 14 days
		Gastrointestinal hemorrhage within the past 21 days
		Blood pressure above 185 mmHg sys./105 mmHg dias. after BP treatment
		Coagulopathy, incl. tumour-associated (e.g. in patients with leukaemia) and prolonged aPTT
		Thrombocytopenia $< 100,000$
		Pregnancy (IVT may be considered as off-label treatment)
		Ischemic stroke within the past 2 months
		Septicaemia
		Hypoglycaemia < 2.7 mmol/l or hyperglycaemia > 22.2 mmol/l
		Hyponatraemia or hypernatraemia (< 120 mmol/L or > 150 mmol/L)
		Lumbar puncture < 24 h
		Severe underlying disease, short life-expectancy

Notes

IVT in patients previously treated with antiplatelet aggregation therapy

- Monotherapy: aspirin/clopidogrel/aspirin+dipyridamole/ticagrelor: no restrictions
- Dual therapy: aspirin+clopidogrel: no restrictions; other combinations: consider IVT carefully
- Monotherapy or combination therapy with prasugrel: consider IVT carefully
- Triple therapies: no IVT


Bridging (IVT + EVT)

- As a rule, full-dose thrombolysis – even after complete recanalization, if the alteplase infusion is still running recanalization in the context of thrombectomy
- As a rule, no follow-up imaging before EVT (endovascular therapy), unless there is dramatic clinical deterioration or improvement (e.g., only mild symptoms, such that EVT would no longer be indicated)
- **Large infarct core DWI/CBV (> 150 mL):** consider EVT in younger patients (< 75 years, and especially if < 60 years)
- **IVT for non-disabling deficits in the early time window NOT recommended, then DAPT with loading is preferred**
- [Prognosis assessment for participatory decision-making for borderline thrombectomy decisions](#)

IVT Dosage

Weight	Alteplase (Actilyse®)			Weight	Tenecteplase (Metalyse®)
(kg)	Total dose 0.9 mg/kg	Bolus 10% in 1 min	Perfusor 90% over 60 min	(kg)	0.25mg/kg KG as bolus within 5-10 sec
44-47	40 mg = 40 ml	4 ml	36 ml/h	<60	15 mg = 3.0 ml
48-51	44 mg = 44 ml	4 ml	40 ml/h	≥ 60 bis < 70	17 mg = 3.5 ml
52-54	47 mg = 47 ml	5 ml	42 ml/h	≥ 70 bis < 80	20 mg = 4.0 ml
55-57	50 mg = 50 ml	5 ml	45 ml/h	≥ 80 bis < 90	22.5 mg = 4.5 ml
58-62	54 mg = 54 ml	5 ml	49 ml/h	≥ 90	25 mg = 5.0 ml
63-67	59 mg = 59 ml	6 ml	53 ml/h		
68-72	63 mg = 63 ml	6 ml	57 ml/h		
73-77	68 mg = 68 ml	7 ml	61 ml/h		
78-82	70 mg = 70 ml	7 ml	63 ml/h		
83-88	77 mg = 77 ml	8 ml	69 ml/h		
89-92	80 mg = 80 ml	8 ml	72 ml/h		
93-97	86 mg = 86 ml	9 ml	77 ml/h		
≥98	90 mg = 90 ml	9 ml	81 ml/h		

IVT in case of known DOAC intake (<48h)



If last intake >48h (normal renal function) IVT generally possible.

1) Idarucizumab (2x2.5 g i.v. before IVT);

2) POC INR to exclude other coagulopathy. Waiting for levels optional.

3) Only applicable in the early time window (<4.5h).

In case of unclear benefit/risk situation consult stroke specialist. In case of stroke under DOAC, **always order substance-specific levels** (compliance).

Monitoring during IVT + EVT

IVT

1. Measure BP every 15 minutes for 2 h after IVT:

- target sys. ≤ 185 mmHg, diast. ≤ 105 mmHg
- in the case of > 185/105: re-check after 5 minutes
- if hypertension persists > 185/105: initiate BP reduction (see Antihypertensive medications, below)

2. Respiration: monitor oxygen saturation: target Biox > 92%

3. Evaluation of pupils: 3 × per hour

- in case of clinical deterioration: stop thrombolysis (only possible with Actilyse) CT scan: check for intracranial hemorrhage
- in case of allergic reaction: stop IVT immediately, administer clemastine (Tavegil®): 1 ampoule, methylprednisolone (Solu-Medrol®) 250 mg i.v.

- for severe anaphylaxis: 0.3–0.5 mg epinephrine intra-muscularly; for very severe anaphylaxis: epinephrine 0.05–0.1 mg i.v.
- For orolingual angioedema: epinephrine (0.1%) 0.3 mL s.c. or 0.5 mL nebulized, early contact with anesthesia (fiberoptic intubation) if base of tongue, pharynx or larynx affected
- Reserve treatment for very severe cases: Firazyr® Icatibant 30 mg s.c. (abdominal) — stored in antidote cabinet (UKN), repeat up to 2x within 24h
- if plasma glucose > 11 mmol/l: reduce carefully with insulin

EVT: during EVT Target systolic BP: 140–180 mmHg. After thrombectomy: target BP ≤ 180/105 mmHg; only raise BP if haemodynamic symptoms or infarcts are present

Antihypertensive medication (iv)

Use (standard values)	Medication	Dosage	Maximum effect	Warnings/Side effects
bolus administration	Urapidil 50 mg/vial	2.5–10 mg (1 ml = 5 mg) max 50 mg/d	10 min	Vertigo, headache, dyspnoea, arrhythmia (tachycardia or bradycardia)
bolus administration for HR > 70/min	Labetolol 100 mg/vial	5–10 mg (1 ml = 5 mg) max 200 mg/d	15 min	Bradycardia, AV-block, hypotension, vertigo, nausea, paresthesia, bronchial spasm
bolus administration for HR > 70/min	Metoprolol 5 mg/vial	1–2.5 mg (1 ml = 1 mg) max 15 mg/d	5 min	Bradycardia, AV-block, low output syndrome, bronchial spasm
bolus administration for HR < 70/min	Dihydralazin 25 mg/vial	6.25 mg slowly over 2 minutes (1 ml = 12.5 mg) max 100 mg/d	20 min	Oedema, tachycardia, angina pectoris; exercise caution in the case of liver or renal failure CI: Coronary insufficiency
Perfusion therapy	Urapidil 50 mg/vial	5–10 mg/h max. 40 mg/h	–	Restricted to 48 h therapy
Perfusion therapy	Labetolol	10–40 mg/h max 100 mg/h (1 ml = 1 mg)	–	Bradycardia, AV-block, hypotension, vertigo, nausea, paresthesia, bronchial spasm
Perfusion therapy	Cleviprex® Clevidipin	2–16 mg/h max 32 mg/h (1 ml = 0.5mg)	–	Only short time! At the same time initiate oral medication. Side effects: Headache, afib, tachycardia, dizziness, hypotension, Contraindication: allergy (soy, egg), critical aortic stenosis

Vasopressor therapy (iv)

Use (standard values)	Medication	Dosage	Warnings/Side effects
Perfusion therapy	Norepinephrine® 50 mg/vial	Start with 0.01 µg/kg BW/min then titrate	CI: Hyperthyreosis, tachycardia arrhythmias, angle-closure glaucoma, pheochromocytoma, cardiomyopathy (esp. hypertrophic) Compensate hypovolaemia first

Monitoring on the Stroke Unit

First neurological examination immediately upon patient's arrival

Cardiovascular monitoring:

- BP upper limits during the early phase (especially first 24 h):
- **≤ 180/105 mmHg after IVT or EVT; ≤ 220/110 mmHg if conservative treatment**
- BP lower limit: only in individual cases such as patients with hypoperfusion/clinical deterioration due to drop in BP => to increase BP: temporary administration of a limited volume of infusion solution (max. 500 ml); in other cases use vasopressors (typically Norepinephrine)
- Tachycardia > 100 bpm => usually beta blockers; in case of tachycardic atrial fibrillation consider adding digoxin
- Frequent ventricular extrasystole => magnesium 2 g i.v.
- Bursts of ventricular extrasystole (more than 3 beats): usually beta blocker + magnesium; ≥10 beats or polymorphic or >120/min or clinically symptomatic => consultation with cardiologist
- Bradycardia: during sleep in asymptomatic patients, usually up to 35 bpm is tolerable
- Pause > 3 seconds => consultation with cardiologist

Respiration: target Biox ≥ 92; screening for sleep apnoea

- If > 4l O₂/min is necessary or respiration frequency > 20 => clinical examination, arterial blood gas analysis, chest X-ray (pulmonary embolism? cardiac failure? pneumonia?)
- If respiration frequency > 25–30 danger of respiratory exhaustion

Body temperature: ≥ 38° -> antipyretics (1st choice paracetamol) + 2x2 blood cultures, empirical/causal treatment

Neurological evaluation: usually every 2h during the first 24h after IVT/EVT or symptomatic stenosis, otherwise every 6h

Clinical general medical evaluations: cardiac compensation, lungs, abdomen to be checked daily

Prescription of medication:

- Do not prescribe antiplatelet aggregation therapy after IVT/i.a Urokinase before exclusion of hemorrhage in control CT/MRI after 24h
- General cardiac premedication should be continued, with potential reduction of dose (WARNING cardiac failure/rebound tachycardia after stop)
- Stop any antihypertensive medication in the case of haemodynamic stroke

Laboratory controls: (24h after IVT/EVT)

- Hb, Lc, Tc, CRP, glucose, Na, K, creatinine, INR
- hs-Troponin T and ECG after 3 h if initially >5x ULN or acute coronary syndrome
- Anaemia: transfusion if Hb < 90 g/l
- Platelets every 2-3 days under heparin therapy; further laboratory examinations individually determined

Neuroradiological control:

- 24h after IVT/EVT, MRI (or CT), including MRA (CTA) except in patients with severe renal insufficiency
- In case of neurological deterioration (usually NIHSS worsening of 2 points or more) immediately

Swallowing: in case of dysphagia, reduced consciousness, facial palsy or relevant

neuropsychological deficits: swallowing test (GUSS: Gugging Swallowing Screen) —> if suspicious or brain stem ischemia: FEES

Nutrition and fluid balance:

- Daily fluid intake requirement: 30–35 ml/kg body weight: If volume administration is necessary: infusion as bolus (either 500 ml i.v. or as free water via ng tube); if volume status unclear: ultrasound (inferior vena cava, lungs, bladder)
- Daily energy demand: 35 kcal x body weight
- If sufficient oral energy supply cannot be given within 3 days after stroke: enteral feeding via nasogastric tube with high caloric fibrous enteral feeding as bolus application 3–4x/d; control of electrolytes (incl. magnesium and phosphate)
- If fasting period > 7 days: delayed feeding (WARNING refeeding syndrome)

Monitoring after IVT/EVT + Mobilization

	Vital signs (BP, Pulse, BiOx)	Target BP	NIHSS + GCS	Mobilization
IVT	Every 5 minutes until BP is <185/105 mmHg for 2 consecutive readings Every 15 minutes up to 2 hours after IVT, then every 30 minutes up to 6 hours, then every 60 minutes up to 12 hours	<185/105mmHg	Angioedema Every 10 minutes during the first 60 minutes NIHSS + GCS Every 30 minutes up to 2 hours, then every 60 minutes up to 6 h Afterwards, 3 + 1	Mobi 1 until 6h, then Mobi 3 if the patient is stable
EVT	Every 5 minutes until BP is <185/105 mmHg for 2 consecutive readings. Every 15 minutes up to 2 hours, Every 60 minutes up to 6 hours.	<185/105mmHg	General: Every 6h (3+1) If re-thrombectomy "yes": Every 60min during the first 12h	Bed rest after angiography as prescribed Generally Mobi 3
IVT+EVT	As for IVT	<185/105mmHg	Same as for lysis	Same as for lysis (+bed rest post-angio)
Symptomatic, severe, non-revascularized stenosis	Every 120 minutes up to 24 hours or until revascularization (as determined by the senior stroke physician)	<185/105mmHg	Every 120 minutes up to 24 hours or until revascularization (as determined by the senior stroke physician)	Mobi 3
Intracerebral bleeding	Every 5 minutes until target blood pressure is reached twice in a row. Then, every 30 minutes for 2 hours. Then, every 60 minutes	<140/90mmHg	Every 6h (3+1)	Mobi 2 within the first 24 hours/ control image, then reevaluation.
All other strokes	Every 6h (3+1)	210/105mmHg	Every 6h (3+1)	Mobi 3

Mobilization stages: Stage 1: 30°, up to max. 60° Stage 2: Bed edge & armchair (by day 2 at the latest) Stage 3: Walking with assistance, if safe to do so. Possible delayed mobilization in cases of: deterioration in orthostasis, localization in the pons/perforator, hemodynamic infarction with penumbra. In patients with treatment limitations (i.e., no re-thrombectomy, no intensive care measures after lysis bleeding), the GCS/NIHSS monitoring scheme may be deviated from (then 3+1, delirium prevention).

Daily checklist – visiting stroke patients

1	Neurological evaluation	NIHSS and symptom-orientated functional examination (results of physio-, ergotherapy, speech therapy); depression? sleep-wake disorder?
2	Clinical evaluation	Cardiac compensation, lung, abdomen, fever?
3	Monitoring	Relevant rhythmic disorders (regarding reason, haemodynamic, cardiac pathology) BP target value? BP actual value?
4	Mobilization?	
5	Nutrition, dysphagia?	
6	Laboratory controls?	Especially electrolytes, inflammatory parameters, renal, haemostasis
7	Medication	Antithrombotic therapy? Deep vein thrombosis prophylaxis? BP therapy?

Systematic AF Monitoring

1	graphical 24h-Spectrum of heart rate
2	Identify and analyze sudden raise/drops
3	Identify and analyze abrupt volatility in amplitude of the heart rate variability
4	Analyze episodes with heart rate >120/min or <40/min
5	Evaluation of all detected arrhythmia episodes by the automatic ECG analysis software
6	Chronological analysis of beat-to-beat irregularities in RR intervals and atrial fibrillation

Kallmünzer et al. Stroke 2012
Supported by

DD Checklist neurological deterioration

- ? Reinfarction
- ? Infarct localization: e.g. secondary deterioration more frequent in internal capsula or pontine infarctions
- ? Haemodynamic: BP associated? Associated with mobilization?
- ? Bleeding
- ? Rising ICP
- ? Epileptic seizure / non-convulsive status epilepticus
- ? **Infection**
- ? **Sedation**
- ? Psychogenic
- and other less frequent causes

Thrombolysis-associated bleeding

In case of symptomatic intracranial hemorrhage (parenchymal haematoma + neurological deterioration within 24 hours after thrombolysis administration, consult stroke specialist):

- **Stop thrombolysis** (only possible with Actilyse; Tenecteplase given as a bolus)
- **Blood pressure target $\leq 140/90$ mmHg**
- Emergency CT scan; if bleeding is confirmed: → Contact on-call Neurosurgery *6310 and Haematology *6220
- **Tranexamic acid** (Tranexam OrPha) IV 1000 mg over 10 minutes
- **Fibrinogen** (Haemocomplettan P) or **prothrombin complex concentrate** (Prothromplex®) after consultation with haematology
- **Blood tests:** Platelets, INR, aPTT, fibrinogen, crossmatch blood sample

Prevention of deep vein thrombosis

- In case of IVT, bridging, Urokinase initiation: after exclusion of cerebral hemorrhage in the follow-up-imaging
- After mechanical thrombectomy without IVT and with conservative therapy: start immediately
- Under heparin platelet control on day 1, then every 3 days (HIT?, 4Ts score)
- Pneumatic compression stockings may be an alternative if LMWH is contraindicated

DD myocardial infarct vs stress cardiomyopathy

hsTnT-elevation in approx. 20% of ischemic stroke patients, DD: MI, stress cardiomyopathy (SCM), renal failure, hypertensive crisis, tachycardia, aortic dissection

Variable manifestation of SCM: hsTnT ↑ < regional hypokinesia < transient apical ballooning

- An increase >5x the upper normal limit (Troponin) indicates a Type 1 myocardial infarction. A dynamic rise does not reliably differentiate between Type 1 myocardial infarction and stress cardiomyopathy
- Stress cardiomyopathy remains a diagnosis of exclusion
- In case of doubt, consider a cardiac MRI

Possible practical approach in case of hsTnT-elevation:

- Clinical correlate for MI (repolarization disturbance, wall motion abnormalities, angina pectoris) → coronary angiography
- No clinical correlate: repeat ECG and hsTnT after 1 and 3 h, and, if necessary, after 6 h:
 - hsTnT without relevant change (<20%): renal failure? heart failure? hypertensive state?
 - hsTnT change >20%: consider cardiac MRI or coronary angiography

Malignant infarcts

General

- Usually 30° supine position
- BP aim: MAP > 85 mmHg, sys. < 220 mmHg
- **In case of imminent craniectomy: stop antiplatelet therapy**
- Pneumatic compression stockings for prevention of deep vein thrombosis
- Consider as emergency medication until craniectomy:
 - mannitol/hypertonic saline solution (dosage control of mannitol via osmotic gap, hypertonic saline solution via Na and osmolality)
 - Hyperventilation

Decompressive craniectomy

- **Craniectomy if possible within 24–48 h** and before relevant neurological deterioration
- Critical phase with risk for neurological deterioration: 24–96 h (rarely up to as late as 10 d)
- Signs of rising ICP: decreasing consciousness, disturbance of pupillomotor function usually with dilatation in case of supratentorial swelling, and miosis in case of infratentorial swelling, increasing paresis, new ipsilateral paresis, pathological breathing pattern, rhythmic disorders
- **Possible practical approach:**
 - general actions see above
 - frequent clinical control and early CT control (e.g. 12 h after stroke) in case of infarct >2/3 middle cerebral artery territory or larger infratentorial stroke (e.g. complete PICA infarct or larger)
 - aim: preventive planned decompression! An emergency rescue decompression only in exceptional circumstances since it is associated with worse outcome

Malignant infarctions of the middle cerebral artery territory

Predictors for malignant infarction: young patient, no atrophy, persistent vessel occlusion, early midline shift ≥ 4 mm, critical infarct volume dependent upon age/atrophy but >>80 ml or >1/2 media territory, additional infarction in anterior or posterior territory

Indications for craniectomy

1. Usually < 60 years, individually consider also in older patients
2. Symptom onset within the past 48 h (in exceptional cases this may be longer)
3. Infarction of at least half of the middle cerebral artery territory
4. Consent of patient or family
5. Indication independent from affected hemisphere (dominant vs. non-dominant)

Contraindications

1. Bilateral fixed pupils and coma
2. More than 3 of the following unfavourable prognostic factors:
 - a. age >50 years
 - b. infarction extends beyond the middle cerebral artery territory
 - c. unilateral dilated pupil
 - d. GCS <8
3. Severe comorbidity; severe preexisting disability

Malignant cerebellar infarctions

Predictors for malignant infarction: young patient, persistent vessel occlusion, bilateral infarction, the size has less predictive value because small infarcts may induce large oedema

Indications for craniectomy

1. Larger infratentorial ischemia (e.g. complete PICA stroke)
2. Imaging shows space-occupying infarction with progression in short term follow-up imaging
3. Consent of patient or family

Contraindications

1. Clinical or imaging signs of severe irreversible brainstem damage
2. Severe comorbidity, severe pre-existing disability

Agitation/delirium


General				
• Screening: CAM (Confusion Assessment Method) or IDCSC or 4-AT • Follow-up parameter: RASS (Richmond Agitation Sedation Scale):				
+4 combative	+3 very agitated	+2 agitated	+1 restless	0 alert and calm
−5 unarousable	−4 deep sedation	−3 moderate sedation	−2 light sedation	−1 drowsy
Diagnostic criteria ICD-11				
Required: - Disturbance of attention, orientation and consciousness that develops within a short period of time (e.g. within hours or days) and usually fluctuates. - Change compared to the previous state. - Not better explained by pre-existing disorder (e.g. MCI / dementia or psychiatric illness) or intoxication. - Trigger: disease, substance or medication, withdrawal, multiple or unknown factors				
Additional possible clinical features: - Global cognitive impairment (multiple domains) - Impaired perception (illusions, delusions or hallucinations) - Emotional disorders (anxiety, depressive mood, irritability, anger, euphoria or apathy) - Behavioral symptoms (e.g. restlessness, agitation, impulsivity, sleep-wake rhythm)				
Treatment				
1. Eliminate/treat cause 2. Non-drug therapy measures • circadian rhythmization • Stimulus reduction				
Symptomatic therapy				
In case of alcohol withdrawal delirium, 1st choice is benzodiazepines (and thiamine, see below), otherwise use the following scheme: Level 1: Pipamperone 20 mg stepwise (maximal dose 160 mg/d) or Quetiapine 12.5 mg stepwise (maximal dose 400 mg/d) or/and Risperidone 2x0.5 mg/d (maximal dose 6 mg/d) or exceptional Haloperidol (Haldol®) 0.5–1 mg stepwise (maximal dose 20 mg/d) WARNING: arrhythmia → apply i.v. only exceptionally under monitoring Level 2: Clonidine: 25–50 µg as bolus, then 25–150 µg/h perfusion therapy (maximal dose 150 µg/h) Level 3: Dexmedetomidine (Dexdor®): 0.2–1.4 µg/kgKG/h (starting dose 80kg = 40 µg/h = 5 ml/h) CAVE: contraindication hypotonia, bradycardia, AV-block II/III° Level 4: Propofol perfusion in ICU				
Special case, delirium in patients with stroke and Parkinson's disease → Quetiapine (Seroquel®) 25–100 mg p.o., max. 300 mg/d → Clozapine (Leponex®) 6.25–12.5 mg, max. 100 mg/d; 2/3 of the dose at night, 1/3 throughout the day				
Delirium due to alcohol withdrawal: → primarily benzodiazepines + thiamine substitution Diazepam (Valium®) 5mg intravenously (increase possible up to 10mg intravenously) or midazolam (Dormicum®): 2.5–5mg as a bolus (maximum dose 10mg) i.v. then if necessary 2–5 mg/h via perfusion (maximum dose 10mg/h); antidote: flumazenil (Anexate®)				

TIA

Pathological/anatomical TIA definition: transient focal neurological deficit without DWI lesion on MRI

Time-based TIA definition: transient focal neurological deficit max. 24h duration

Definition Minor-Stroke: NIHSS Score < 4, symptoms stable or regressive



Risk factor	Points
Age ≥ 60 years	1
Systolic BP ≥ 140 or diastolic ≥ 90	1
Unilateral weakness with or without speech disturbance	2
Speech disturbance without weakness	1
TIA duration ≥ 60 min	2
TIA duration 10–59 min	1
Diabetes mellitus	1

ABCD2 Score

6–7 points: high 2-day risk (8%)
 4–5 points: intermediate 2-d risk (4%)
 0–3 points: low 2-day risk (1%)

DD TIA DD Migraine with Aura

Motor symptoms → primarily ischemic

Purely negative visual/sensory symptoms → rather ischemic;

Positive sensory or visual symptoms → DD ischemic, DD aura;

A migraine aura almost always has visual symptoms, even at an advanced age

Supported by

Diagnostic work-up

Frequent causes (ASCOD , TOAST)		Other (rare) causes
≈20%	Small vessel disease (mostly single perforator occlusion; <15mm CT, <20mm MRI), no AF, no ipsilateral stenosis	Anti-Phospholipid Syndrome, Factor V Leiden
≈25%	Cardioembolic	Iatrogenic (e.g. periinterventional)
esp.	Atrial fibrillation / flutter	Vasculitis
	(Sub)acute myocardial infarction	Tumor-associated and other coagulation disorders (esp. DIC)
	Endocarditis	Drugs, Medications
≈20%	Large artery disease	Other arrhythmia (e.g. sick sinus), valvular vitium
esp.	Arterio-arterial embolism (ICA, VA Stenosis), ICAD	Chronic infection (esp. HIV, Hep B/C, syphilis)
	Aortoembolic (also from Aorta descendens possible)	R-L-Shunt pulmonary
	Non-arteriosclerotic Vasculopathy (e.g. FMD, Carotid Web)	Fabry disease, other genetic mutations
<5%	Dissection (cervical vessels, less frequent Aorta), especially among young stroke patients	Sickle cell anemia/other hemolytic crises
≈5%	PFO/ASD –associated, esp. among young patients	Polyglobulia/thrombocytosis

Etiological DD according to results

DD according to medical history and physical examination

- ? Valsalva or immobilisation (PFO/ASA)
- ? Positive familial history with onset < 40 years (Fabry disease, coagulopathy)
- ? < 50 years, previous art/ven thrombosis, abortion (anti-phospholipid syndrome), Fabry disease
- ? Throat/neck/eye pain, trauma, Horner, Tinnitus (dissection ICA/VA)
- ? Headache (vasculitis), thunderclap headache (reversible vasoconstriction syndrome)
- ? Heart murmurs, skin or retinal lesions (endocarditis, valvular calcification)
- ? Angina pectoris (acute or in the past)
- ? Acute chest/back pain (aortic dissection!, coronary syndrome)
- ? Peripheral vascular examination incl. BP-difference left-right (aortic dissection)
- ? Skin lesions (septic emboli, Fabry: angiokeratoma, Sneddon: livedo racemosa)
- ? Vision disturbance + hearing disturbance (Susac's syndrome => corpus callosum affected?)
- ? Signs of systemic rheumatic disease
- ? B symptoms, age >75, D-Dimer >1000µg/L, female sex, multiterritorial ESUS (tumor —> screening)
- ? Acute or chronic infection

DD according to laboratory results

- Signs of infection: Infection-associated coagulopathy? Malignancy? Endocarditis? Systemic disease?
- Thrombocytopenia/Thrombocytosis, Leucocytopenia: haematological disease?
- Anaemia: Malignancy? Sickle cell anaemia?
- D-Dimer
 - < 500: more likely arterio-arterial, aorto-embolic, microvascular
 - 500–3000: associated with atrial fibrillation
 - > 3000: Malignancy? Coagulopathy? -> screen for malignancy and consider thrombophilia screening

DD according to MRI

- > 2 vessel territories affected: cardio-embolic, aorto-embolic, coagulopathy (D-Dimer? Fibrinogen?), paradoxical embolism, vasculitis
- 1 vessel territory with multiple ischemia (be aware of circle of Willis variants): arterio-arterial (Plaque-MRI?)

Standard diagnostic work-up


- **MRI incl. MRA** (for a reliable evaluation of the distribution pattern of acute/chronic infarction and determination of the etiology, especially in view of a CEA!); if not possible, or CT incl. CTA
- **Neurovascular ultrasound** in the case of relevant stenosis, arterio-arterial embolization or R/L-shunt (PFO)
- **12-lead ECG**
- **Long-term ECG** (see scheme below)
- **Cardioaortic Imaging** (see decision pathway, p. 20)
- **Respiratory Polygraphy**: To be performed according to the discussion during ward rounds (NOT if the patient is from outside the canton, if no clinical consequence is expected — e.g., in cases of multimorbidity — or if there is a clear stroke etiology unrelated to cardiovascular risk factors, such as PFO or dissection)
 - AHI ≥ 30/h: → Referral to sleep clinic promptly → Or, in individual cases: initiation of PAP therapy education during the acute phase
 - AHI 10–29.9/hour: → Sleep outpatient clinic in 3 months → SWEZ triage may organize respiratory polygraphy (RP) or polysomnography (PSG) if needed
 - AHI ≤ 10/hour: → Only refer to outpatient clinic if: Epworth Sleepiness Scale ≥ 10, or Nocturnal Apnea Score (NoAS) ≥ 8
- **Routine laboratory testing**: Na, K, CRP, ESR, glucose, HbA1c, creatine, urea, hs-Troponin T, CK, CK-MB, AST, ALT, GGT, TSH, pro-BNP, D-dimer, complete blood count, coagulation state, blood lipids
- **< 50 years and no other apparent etiology**: additionally lupus anticoagulant, anti-cardiolipin (IgG+M, not A!), anti-b2GPI (IgG+M, not A!) (if elevated after 3 months, repeat).

12-channel ECG and 72h continuous ECG monitoring for a minimum of 72 hours

AF diagnosis: manage according to guidelines

Risk Stratification for AF

Riskfactor	Comparative low	Comparative high
Patient characteristics		
Age, years	<60	≥75
Manifest heart failure, peripheral or coronary artery disease	Absent	Present
Echo-markers		
Left ventricular ejection fraction	Normal	<40%
Left atrial dilatation	Diameter <40mm	>45mm LAVI >42 ml/m ²
Monitoring on the stroke unit	SVES <120/24h Atrial run <5 beats	SVES ≥500/24 hours Atrial runs >20 successive beats/24h
Blood Biomarkers		
MRproANP	<92 pmol/L	>200 pmol/L
NTproBNP	<200 pg/mL	>400 pg/mL



- **Monitoring only if anticoagulation or LAAO is an option**
- In addition to initiating anticoagulation, **all aspects of the holistic ABC care bundle should be optimized** after the diagnosis of atrial fibrillation ([ESC Guidelines](#)).
- In addition, **rhythm control measures should be considered and discussed** in patients with atrial fibrillation diagnosed within the last 12 months:
 - **Rhythmology consultation on stroke unit** (start antiarrhythmic drugs?)
 - **Referral to rhythmology after discharge** for evaluation of ablation 2–3 months after event
- Oral anticoagulation is indicated for secondary prophylaxis if atrial fibrillation lasts >30 seconds in a **Holter ECG** or >6 minutes in an **implantable event recorder**, pacemaker, or ICD

Cardioaortic Imaging

TTE: Standard imaging, especially in patients with a known etiology

TEE with the following criteria:

- Suspicion of endocarditis (urgent)
- <60 years: no other etiology (e.g. dissection, carotid web, etc.)
- 60-80 years: no other etiology, no cardiovascular comorbidities and low peri-interventional risk

Remark:

- If endocarditis is suspected and initial TEE non-diagnostic, repeat TEE after 3-5d and evaluate PET-CT
- Consider TEE in case of multiple or multi-temporal ischemia

If specific pathology(ies) suspected:

- TEE/TTE combined
- Cardioaortic MRI*
- Cardioaortic CT*

*In a timely manner on an outpatient basis or from rehabilitation if inpatient treatment is not possible.

Pathology	TTE	TEE	Cardioaortic CT*	Cardioaortic MRI*
LV Thrombus	++ (CE)	+ (CE)	++	+++
LA/LAA (Thrombus)	+	+++	+++	++
PFO / ASD also order nvUS TCD	+	+++	+	+
Valvular pathology - native - on bio/mech. valve	++ ++	+++ ++	+++ (Valve-CT) +++ (Valve-CT)	+ +
Intracardiac tumor or metastasis	+	++	++	+++
Aorta (Atheroma, Dissection)	-	++	+++	++
LV function, LV aneurysm	++	++	++	+++
Cardiomyopathy	++	+	++	+++

PFO-associated stroke

RoPE Score (Risk of paradoxical embolism):

The RoPE score was developed to identify patients with cryptogenic stroke and PFO in whom the PFO was likely the cause of their stroke.

A high RoPE score in a patient with a cryptogenic embolic ischemic stroke and PFO and no other convincing etiology strongly suggests, but does not prove, that the causality of the stroke is related to the PFO.

The RoPE score **should not** be used to decide which stroke patients should undergo echocardiography.

The RoPE score **should not** be used alone to decide which cryptogenic stroke patients with PFO should undergo PFO closure (see PASCAL classification below).

					Sum 0-3	0% attributable risk
No arterial hypertension	1	Age 18-29	5		Sum 4	38% attributable risk
No Diabetes mellitus	1	Age 30-39	4		Sum 5	34% attributable risk
No prior Stroke/TIA	1	Age 40-49	3		Sum 6	62% attributable risk
Non-Smoker	1	Age 50-59	2		Sum 7	72% attributable risk
Cortical infarct location	1	Age 60-69	1		Sum 8	84% attributable risk
		Age ≥ 70	0		Sum 9	88% attributable risk

Kent et al. Neurology 2013
Kent et al. Jama 2021

PASCAL Classification

Only correctly applicable between 18-60 years. In the case of cryptogenic stroke (at least 72h ECG without atrial fibrillation), closure is generally indicated in patients < 60 years of age. In addition to age and vascular risk factors (RoPE), the concomitant circumstances that may favor a paradoxical embolism (e.g. evidence of leg vein thrombosis, onset of neurological symptoms in connection with a Valsalva maneuver), as well as any psychological factors, should be taken into account. At the age of 60-80 years, individual decision on closure taking into account the RoPE and PASCAL score.

		RoPE <7	RoPE ≥ 7
High	Simultaneous pulmonary embolism or DVT + PFO with ASA or large shunt	Likely	Very likely
Medium	PFO with large shunt or atrial septal aneurysm	Possible	Likely
Low	Small PFO without atrial septal aneurysm	Unlikely	Possible

After PFO closure, continue platelet aggregation inhibitors in the long term if well tolerated.

(A)symptomatic artery stenosis

Criteria for the classification of symptomatic carotid artery stenosis: (Judgement always by a vascular neurologist)

- very likely: proof of a plaque rupture with apposition thrombus in CT/MR-angiography
- probable: internal carotid artery stenosis of at least 50% + typical stroke distribution pattern in MRI, with no other cause of the stroke (TEE/TTE and at least 24-hour ECG monitoring test)

In general: CEA/stenting usually within a few days after symptom onset

- for high-grade asymptomatic stenosis and potentially symptomatic medium/low-grade stenosis consider plaque imaging (ultrasound, plaque MRI) and consider information for revascularisation
- **always high-dose statin therapy, for antiplatelet aggregation therapy see below**
- Decision CEA or CAS should be taken in an interdisciplinary board

ICA stenosis extracranial	in case of CEA, elective: • normally pre- and postoperative aspirin 100 mg or clopidogrel 75 mg monotherapy (stroke occurrence under aspirin or clopidogrel: consider aspirin 100 mg + clopidogrel 75 mg perioperatively) • in case of additional atrial fibrillation, as long as OAC is possible (depending upon infarct size): begin aspirin 100 mg 1 d preoperatively, therapeutic heparinization until surgery. After surgery: 7 d aspirin 100 mg + prophylactic heparin, then stop aspirin/heparin and begin (D)OAC
	in case of stenting, elective: • preinterventional aspirin 100 mg + Ticagrelor 90mg or clopidogrel 75 mg (possibly loading dose); postinterventional DAPT for at least 6 months (depending on stent type, result after stenting, follow up results), then monotherapy • in case of additional atrial fibrillation, as long as anticoagulation is possible (depending upon infarct size): normally N(OAC) + aspirin 100 mg; start aspirin at least 1 day before intervention
	In case of CAS (stenting) during acute intervention: • Aspirin 250–500 mg i.v. during stenting, control imaging afterwards for exclusion of bleeding, then start Clopidogrel, 75 mg (preferably without loading or loading with only 150 mg) • In case of hemodynamic dependence on the stented vessel: early control imaging after 2–6 h to rule out bleeding, then clopidogrel OR ticagrelor (whenever possible with loading after weighing up the benefit/risk) • If there is a tendency to reocclusion or thrombus formation in the angio: DAPT loading via gastric tube and temporary Integrilin perfusor OR Cangrelor i.v. (loading Ticagrelor, then stop Cangrelor)
	If apposition thrombi are detected: Stenosis degree > 50%: CEA/stenting as soon as possible, if necessary prior transient therapeutic heparinization (first choice: low molecular weight heparin) + high-dose statin +/- aspirin (case-by-case decision) Stenosis degree < 50%: therapeutic heparinization (first choice: low molecular weight heparin) + high-dose statin +/- aspirin , follow-up MRI after 2–3 days; CEA/stenting if new ischemias are detected or persistent thrombus; consider conservative management if thrombus regresses
Stenosis of vertebral artery origin	Stenting normally only in cases of failure of best medical treatment (including transient therapy with aspirin + clopidogrel) preinterventional aspirin 100 mg + clopidogrel 75 mg (possibly as loading dose) postinterventional aspirin 100 mg + clopidogrel 75 mg usually for 12 months with drug-eluting stents, otherwise 6 months; then monotherapy
Intracranial artery stenosis	Aspirin 100 mg + clopidogrel 75 mg for 3 months, then de-escalate to monotherapy + statin at a high dose (for example atorvastatin 80 mg) Stenting should be performed only in exceptional cases and after failure of medical therapy

Arguments for and against CEA/CAS

	CEA	CAS (Stenting)
Anticipated interventional risk	individually	individually
Technical access	individually	individually
Patient preference	individually	individually
Malcompliance with medications	pro CEA	
Prothrombotic status	pro CEA	
Bleeding tendency, previous bleeding under antiplatelet therapy	pro CEA	
Appositional thrombus with floating parts	preferably CEA	alternatively possible
Severe renal insufficiency	pro CEA	
(D)OAC therapy with low risk upon discontinuation	pro CEA	
Re-stenosis after CEA/CAS		absolute indication
Post-radiation stenosis		absolute indication
Contralateral recurrence paresis		absolute indication
Contralateral carotid occlusion	CEA also possible	preferably pro CAS pro CAS
Indication for (D)OAC with very high risk upon discontinuation	CEA possible if risk not extreme	pro CAS
Mechanical heart valve		pro CAS

Hyperperfusion syndrome

- complication following stenting/CEA, particularly in cases of hemodynamically relevant stenosis
- risk factors: high grade stenosis, bilateral stenosis, perioperative hypertension, reduced reserve capacity, diabetes, female sex, age > 75 years,
- clinical symptoms: headache, seizures, neurological deficits; risk: intracerebral hemorrhage
- occurrence 12 h–7 days after revascularization (max. 28 days)
→ therefore BP should normally be kept at < 140/100 mmHg postoperatively postinterventionally
- in cases of pronounced oedema, additional administration of dexamethasone may be necessary

Dissections

- Data on ASA (acetylsalicylic acid) and OAC (oral anticoagulants) is not conclusive; generally, ASA is preferred; anticoagulation should primarily be considered in the following cases:
 - a) Dissection with cerebral ischemia;
 - b) No vascular occlusion;
 - c) Early onset < 7 days after the initial manifestation
- In cases of dissections that extend into or are located within the intradural region, the use of OAC is relatively contraindicated (increased risk of subarachnoid hemorrhage).
- If MRI findings regarding the dissection sequences are unclear: routinely add diagnostic clarification (especially TEE/TTE, 3 x 7-day EKG) and repeat dissection sequences based on findings
- Off-label use of DOAC may be considered in individual cases

- Duration of secondary prevention with ASA/OAC: If initial treatment was with OAC, switch to ASA after 3–6 months. Continue ASA 100mg/day as long-term prophylaxis based on an individual case decision, considering the vascular status (continue if vascular pathology persists) and other benefit/risk factors.

Supported by

Cerebral vasculitides

1 History • B-Symptoms, recent infections • Headache <i>thunderclap, temporal/occipital pain</i> • Visual, hearing impairment, eye-pain sicca symptoms • Oral/genital aphthae, sinusitis/epistaxis, asthma/cough • Reynaud, arthralgia, skin changes • Previous illnesses – <i>lymphoma/leukaemia</i> • Immunosuppression <i>Diabetes, HIV, immunodeficiency</i> • Medicaments e.g. <i>checkpoint inhibitors</i> • Drugs especially <i>cocaine and amphetamines</i> • Foreign travel/contact with animals unpasteurized milk • Family History	2 Status • General internal status • Auscultation over all large vessels • Palpitation of temporal arteries • Blood pressure at all extremities • Skin: <i>livedo, nailfold bleeding, distal emboli, angio keratoma</i> • Joints: <i>redness, swelling, pressure sensitivity, hyperelasticity</i> • Eyes: <i>visual acuity, ocular fundus</i> • ENT: <i>hearing test, Weber-/Rinne</i>
3 Blood • BSR, CRP, differential blood count, LDH, CK, liver, kidney, ferritin, calcium, TSH, immune fixation + free light chains in serum, IgG/M/A • Coagulation status including fibrinogen, D-dimer, lupus anticoagulant • RF IgM, CCP, ANA, ANCA, SS-A, SS-B, dsDNA, cardiolipin-/beta-2-glycoprotein-IgM/IgG, C3/C4 • Urine drug screening • Infectious serology: HIV, hepatitis B, C, syphilis, VZV, quantiferon test (before starting steroids, otherwise ELISpot) • If there is fever or increased CRP: 3x2 blood cultures (endocarditis scheme)	4 CSF • Standard including IEF • Cytology • If necessary, flow cytometry with CD4+/CD8+ quotient and haemat. Immune cell phenotyping • BioFire, CXCL13, liquor-/serum index for borreliosis, VZV, HSV (consider eubacterial/panfungal PCR) • Preserve 3 spare tubes (in case of suspected tuberculosis one tube with 10 ml) Urine Urine • Urine status, protein/albumin/creatinine quotient • in case of hematuria (WARNING bladder catheter) if necessary, urine sediment by nephrologist
5 Additional examinations • MRI with dark blood- and T1 space sequences, perfusion → if inconclusive: cerebral angiography • nvUS intra- and extracranial vessels • >45 y or ANCA+ : including temporal arteries; large vessel involvement → arm arteries • TEE • CT thorax (abdomen/pelvis if B-symptoms) • Consult ophthalmology: <i>if necessary fluorescence angiography, OCT angiography, vitreous puncture</i> • If necessary, consult rheumatology • If necessary, consult infectiology eubacterial/panfungal PCR, next generation sequencing • Whole body PET in case of unclear large vessel affection/suspicion of sarcoidosis, lymphoma, small vessel vasculitis	6 Biopsy CNS (diagnosis confirmed in 10–30%, alternative diagnosis in 30–50%) • Early pause of antiplatelet agents • target region: contrast enhanced non-eloquent areas; otherwise frontal lobe in non-ischemic area • sample: meninges + cortex + white matter • Analysis incl. bacteriology for detecting acid fast rods, PCR mycobacteria, bacteria, fungi, in case of suspicion, also virus PCR Biopsy other body regions Evaluation before CNS biopsy (<i>eye, temporal arteries, nasal mucosa, lymph nodes, skin, muscle, nerve, kidney, lung, liver, bone marrow</i>)

Note:

Small vessel vasculitis can only be detected with biopsy (MRA and DSA negative)

Radiologically suggestive: multiple ischemias (WARNING DD emboli, coagulopathy, intravascular lymphoma, MELAS, etc.).

Clinically suggestive: clinical findings clearly exceeding the detected ischemia.

WARNING DWI lesion without perfusion deficit → lymphoma?

DD cerebral vasculitides

Primary cerebral vasculitis (PACNS)

(no pathognomonic clinical or paraclinical signs)

- **Clinic** headache (60%), cognitive deficits (50%), seizures (15%), rarely B-Symptoms
- **Blood** Elevated inflammation parameters (< 25%), otherwise normal
- **CSF** Pleocytosis (50%), protein elevation (70%), intrathecal IgG
- **Radiology** ischemic lesions, hemorrhagic lesions (10%), contrast-enhancing lesions (30%), meningeal contrast enhancement (20%), arterial stenosis in MRA (55%) resp. DSA (75%)
- **Biopsy**

Systemic vasculitis/inflammatory disease

- **Takayasu's arteritis:** < 50 years. Carotidodynia, brachial claudication, visual disturbance (retinopathy) → rheumatism (US of the large vessels), MRA thorax/abdomen or PET-CT (before steroid administration)
- **Giant cell arteritis:** > 50 years. B-symptoms, AION/ZAV, temp./occipital headache, intermittent claudication, arthralgia → rheumatism (US temporal artery and large vessels), MRA thorax/abdomen or PET-CT, biopsy temporal artery (before steroids)
- **Polyarteriitis nodosa:** HBV/HCV, B-symptoms, neuropathy/myalgia/CK ↑, arthralgia, palp. purpura/livedo, abdominal sulfamethoxazole, renal failure (no glomerulonephritis), microaneurysms → ANCA neg., abdom. angiography (aneurysms)
- **Kawasaki syndrome:** children, adolescents, fever, conjunctivitis/uveitis, mucous/skin changes, lymphadenopathy → clinical criteria
- **Granulomatosis with polyangiitis:** hypertrophic pachymeningitis, pituitary gland, cranial nerves/neuropathy/mononeuritis multiplex, sinusitis/otitis media, pneumopathy, kidneys (RPGN) → ENT (biopsy NNH), lung pulmonary function, renal (urine sediment)
- **Microscopic polyangiitis:** neuropathy/mononeuritis multiplex, livedo/palp. purpura, kidneys (GN), pneumopathy → nephro. (urine sediment)
- **Eosinophilic granulomatosis with polyangiitis:** mononeuritis multiplex, AION, sinusitis/otitis media, asthma, skin (subcutaneous nodules/ulceration/petechiae), kidneys (GN), eosinophilia → lab. (IgE), ENT (biopsy), lung (BAL, biopsy), kidney (urine sediment)
- **Cryoglobulinaemia:** haematological disorder (monoclonal Ig, MGUS, CLL, myeloma), chronic infection (HIV, HCV, HBV), autoimmune disease (SLE, Sjögren, RA); neuropathy, nephropathy, purpura → lab. (cryoglobulin)
- **IgA-vasculitis (Henoch-Schonlein purpura)** recurrent infection, purpura, arthralgia, abdominal pain, kidneys (GN) → IgA (elevated 50–70%), kidneys (urine sediment), biopsy skin/kidney if necessary
- **Goodpasture syndrome (anti-GBM disease)** kidneys (GN), alveolitis → lab. (Anti-GBM antibodies), kidneys (urine sediment), if necessary skin/kidney biopsy
- **Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis):** uveitis, urticaria, arthralgia, pneumopathy, abd. pain, kidneys (GN), → lab. (C1q/C3/C4), nephro. (urine sediment)
- **Behçet's disease:** brainstem, thalamus/basal ganglia affected, optic neuritis, CSF pleocytosis, thrombosis, oral/genital ulcers, (pan-)uveitis, skin lesion, arthritis → laboratory (HLA B51, IL-6), rheumatology (pathergy test)
- **Cogan's syndrome:** Eye redness/pain (interstitial keratitis), hearing impairment/vestibular symptoms, aortitis, recent infection/vaccination → ophtha, ENT (audiometry), neurotology
- **Rheumatoid arthritis:** (hypertrophy) meningitis, (compression) neuropathy, stiffness/polyarthritis, subcutaneous (+ cerebral) rheumatoid nodules, skin (palpable purpura, ulcer), → lab. (RF/CCP), rheumatology (ultrasound, puncture)
- **Sjögren's syndrome:** Neuro/ganglionopathy, HN, meningitis, myelitis, MS mimic, sicca symptoms, arthralgia/myalgia, skin (palpable purpura), kidneys (TIN) → lab. (cryoglobulin), rheumatology (Schirmer-/Saxontest, ultrasound parotid, biopsy)
- **Sarcoidosis:** Cranial nerves, Pachyleptomeninges, pituitary gland, med. lymphadenopathy, eosinophilia, CSF Glu ↑ Lac ↑, → ACE, Vit. D, PTH, Ca+, CSF (sIL-2R, lysozyme, CD4+/CD8+-Index), CT thorax, pneumo. (BAL with CD4+/CD8+-Index), PET-CT
- **IgG4-associated disease:** pachymeningitis, orbita, pituitary, neuropathy, periaortitis/arteritis, pancreas, salivary gland → lab. (IgG4; 30% normal), biopsy of affected organ
- **Deficit of adenosine deaminase-2 (DADA2):** adolescence, similar to c-PAN, skin, immunodeficiency (IgM ↓), anaemia/leukocytopenia → genetics

Supported by

DD Cerebral vasculitides

Infectious diseases

- **Mycoplasma pneumoniae**: pneumonia, maculopapillary erythema, high erythrocyte sedimentation rate, haemolytic anaemia → *M. pneumoniae* PCR from TBS/CSF and serology, cold agglutinins
- **Bartonella henselae (cat scratch disease)**: cats, fever, lymphadenopathy, neuroretinitis, → Bartonella henselae serology (low specificity) and PCR (low sensitivity)
- **Tropheryma whippelii** farmers, GI symptoms, arthralgia, lymphadenopathy/B symptoms, myorhythmias/supranuclear gaze palsy → T. whippelii PSA staining and PCR CSF (PCR duodenum if necessary)
- **Rickettsial fever (Rocky Mountain spotted fever)**: N-/M-America, fever, headache, petechial rash, anaemia/thrombocytopenia/DIC → serology
- **Leptospira**: contact with rats/mice/farm animals, field work/farmers, fever, kidney/liver involvement → serology
- **Brucella (Mediterranean fever)** raw milk/livestock, meningo-encephalitis, cranial nerve involvement, fever → serology/SAT in serum and CSF
- **Fungi**: Immunosuppression, aneurysms ICA, CAW), perforator strokes → galactomannan/1,3-beta-D-glucan in serum, BAL; culture from CSF; broad-spectrum PCR for fungi (panfungal PCR) if necessary (Unispital Zürich or Basel)

Other

- **Aβ-related angiitis (ABRA)/CAA-related inflammation (CAA-ri)**: Rapidly progressive dementia, marked leukoencephalopathy with enhancement, microbleeds/superficial siderosis → amyloid staining in biopsy

Vasculitis mimics

with vascular changes in imaging


- **Atherosclerosis**: large/medium vessels, vasc. RF, CHD/peripheral arterial occlusive disease, normal CSF (NPV 80–95%), Asian origin, WARNING: also contrast agent-enhancement in MRI
- **RCVS**: see own chapter
- **Vasospasm**: e.g. drug-associated, SAH-associated
- **Intravascular lymphoma (granulomatous cerebral vasculitis)**: DWI abnormalities without perfusion deficit, lymphadenopathy, B-symptoms, history → (intravascular) lymphoma → flow cytometry in serum and CSF (often unremarkable!), EBV serology and PCR, MRI spinal axis incl. cauda equina
- **Radiogenic Vasculopathy**
- **Fibromuscular dysplasia, Marfan-/Ehlers-Danlos Syndrome**
- **Divry van Bogaert-Syndrome, Sneddon's Syndrome** Livedo racemosa
- **Moya-Moya disease**

without vascular change in imaging

- **Endocarditis**: fever, CRP-elevation, stigmata, microbleeds → BK 3x2 incl. HACEK group; if no pathogen Coxiella brunetti and Bartonella henselae; if aseptic (SLE?)
- **Multiple sclerosis/NMOSD/ADEM**
- **Posterior reversible encephalopathy syndrome (PRES)**
- **Lymphoma/glioma**
- **Susac syndrome**: Encephalopathy/CSMZ, sensorineural hearing loss, visual impairment/arterial branch occlusion, corpus callosum/periventricular lesions, leptomeningitis → ophtha. (fluorescence angio, OCT-A), ENT (audiometry)
- **Erdheim Chester disease**
- **Fabry disease**
- **CADASIL**: Migraine with atypical aura, CVI/TIAs, Leukoencephalopathy (temporopolar, capsula externa)/lacunae before age 40 years → CADASIL → NOTCH3-gene
- **RVCL (autosomal dominant retinal vasculopathy with cerebral leukodystrophy)**: Retinopathy CVI/TIA, leukoencephalopathy, migraine, renal insufficiency → TRES 1-gene
- **HERNS (hereditary endotheliopathy with retinopathy, nephropathy, and stroke)**
- **COL4A01-mutation**

Primary CNS Vasculitis – Treatment

NOTE if clinically stable and biopsy negative, consider waiting without therapy and scheduling shortterm follow-up



Cyclophosphamide scheme

Strict verification of the indication

- confirmed CNS vasculitis or highest degree of suspicion despite negative biopsy (PACNS, severe inflammatory cerebral amyloid angiopathy ABRA / CAA-ri)
- CNS / PNS involvement in the context of systemic vasculitis, if without specific therapy

Pre-treatment work-up

- Absolute contraindication: allergy, pregnancy / lactation, severe bone marrow depression, acute infection, severe urinary obstruction; relative: treated HIV, chronic Hep B, latent TBC, previous immunosuppressive therapy, etc.
- Declaration of consent from the patient / relatives
- Risk of infertility: conservation of egg cells (not immediately possible) / sperm, consider GnRH agonist in cooperation with gynecology? Contraception guaranteed up to 6 months after the end of CYC (M and F)
- Clarification of vaccination status / latent infections: HIV, Hep B / C, VZV; HPV in patients with SLE <30Y; possibly TB (quantiferon test), syphilis, malaria, strongyloides, schistosomiasis, etc. for longer stays / origin from risk area / risk profile
- **Vaccinations:**
 - Renewal of regular vaccinations; usually pneumococcal vaccination (Prevenar13 once before the start of immunosuppression), if necessary Hep B according to the rapid scheme (d1, d7, d21 or 3rd vaccination after the end of CYC / before further immunosuppression, especially rituximab)
 - Recommendation for influenza vaccination for patients and close family members once a year
 - Live vaccines (MMR, VZV, yellow fever, oral typhoid): only up to 4 weeks before immunosuppression (and from 6 months afterwards)!
 - Vaccination of those close to the patient, if the patient cannot be vaccinated (especially MMR, VZV, pneumococcus, influenza)
- Prophylaxis Pneumocystis jirovecii pneumonia with Trimethoprim f. 3x / week (if intolerance Dapsone or Atovaquone); if necessary, therapy for latent Hep B, TB, Strongyloides etc. in consultation with Infectious Diseases
- Laboratory: blood count with differential, CRP, transaminases, creatinine, urine status, pregnancy test if necessary, IgG subclasses
- Chest X-ray (TB)
- ECG (QTc for concomitant medication ondansetron)
- with suspected urination disorder residual urine, due to bladder toxicity from CYC!
- **Important: interaction test (especially allopurinol, phenytoin, insulin / antidiabetic drugs, etc.)**
- definition of parameters for follow-up assessment (clinical scores including neuropsychology, CSF, MRI / vasculitis sequences, DSA)

Dose / administration

DGN-Scheme for PACNS / ABRA (= Mayo Clinic / Austin scheme)

- Dose: CYC 750 mg/m² body surface; maximal dose per infusion: 1200 mg
- Time interval: every 4 weeks for a duration of 6 months
- no official scheme for dose adjustment to age and renal function

Cyclops scheme (ANCA-associated vasculitis, if therapy with RTX is not preferred)

- Dose: CYC 15 mg/kg body weight; maximal dose per infusion: 1200 mg
- Administration pulse 1-3 every 2 weeks, then every 3 weeks
- Dose adjustment for age > 60Y and creatinine > 300 µmol / l (Appendix)
- Dose adjustment of further doses depending on the leukocyte nadir:
 - Leukocyte nadir 1-2G / l: dose reduction by 40%
 - Leukocyte nadir 2-3G / l: dose reduction by 20%

Controls / further pulse therapies

Controls: Laboratory: Day 10-14: blood count with differential («Leukocyte nadir»), CRP, transaminases, creatinine

For every sequential pulse:

- Anamnesis: infection / cystitis complaints / hematuria; Laboratory: blood count with differential, CRP, creatinine, urine status, pregnancy test?
- Indication for interruption of therapy with cyclophosphamide:
 - Hematology: leukopenia <3000 / µl, granulopenia <2000 / µl, thrombopenia <100,000 / µl; aplastic anemia (distinguished from inflammatory and bleeding anemia)
 - Urology: non-glomerular hematuria / cystitis
- Documentation of the cumulative CYC dose in the diagnosis (increase in carcinogenicity, risk of hemorrhagic cystitis; maximum cumulative dose 20g)

Re-evaluation

- Usually after 6 months aim for remission-maintaining therapy with alternative immunosuppression (e.g. azathioprine, methotrexate, rituximab); Avoid cyclophosphamide therapy > 12 months or cumulative dose of 25g.

Reversible Cerebral Vasoconstriction Syndrome

Symptoms

- typically thunderclap headache (in about 65%, sometimes with nuchal onset and then spreading to biparietal), lasting minutes to hours, rarely days; often persistence of a milder headache thereafter
- often accompanied by nausea, photophobia, phonophobia
- depending on severity, neurological deficits, epileptic seizures

Typical triggers

- Sex, pressure, coughing, sneezing, urinating, bathing/showering, swimming, laughing, cannabis, cocaine, excess alcohol

CSF

- Cell count increase and protein increase possible → follow-up after 2 weeks

MRA/CTA/DSA

- typically: diffuse vasoconstriction: although it can still increase over a period of weeks (almost complete) reversibility occurs within 12 weeks.

Diagnostic criteria

- acute and severe headache, often thunderclap headache with/without focal deficits or seizures
- monophasic course without new symptoms after >4 weeks
- segmental vasoconstriction in CTA/MRA/DSA
- no aneurysmal SAH
- CSF normal or cell count <15 or protein <100 mg/dl
- complete or almost complete normalization of vasoconstriction within 12 weeks

RCVS₂ score ≥ 5: PPV 98% NPV 67% sensitivity 94% specificity 86%

Use only in patients aged 18-55 years with new onset intracranial arteriopathy to differentiate RCVS from other causes

	Yes	No
Repeated or singular thunderclap headache	5	0
ICA intracranially affected	-2	0
Vasoconstrictive trigger present	3	0
Female sex	1	0
Subarachnoid hemorrhage	1	0

Complications

- Convexity SAH (non-aneurysmal)
- ICH
- Ischemias, especially watershed infarcts
- Reversible encephalopathy syndrome
- Brain edema

Therapy

- No established treatment; consider: nimodipine, verapamil, magnesium sulfate

Cerebral venous and sinus thrombosis

- etiological work-up: infection, coagulation disorder
- Primarily LMWH in therapeutic dosage:** e.g. Enoxaparin (Clexane®) (1mg/kg bw, 2x/d (in a non-randomized study of heparinization, it was even superior in terms of efficacy and hemorrhagic complications; especially in patients with pre-existing congestion hemorrhage)
- alternatively therapeutic heparinization (aPTT 1.5–2.5x baseline aPTT)
- switch to DOAC or Marcumar during treatment** (usually 4–7 days)
- Caution:** anticoagulation is a relative contraindication in Behçet's disease


- continue therapeutic heparinization/LMWH also after occurrence of congestion hemorrhages
- IVT or mechanical recanalization in exceptional cases (e.g., internal cerebral veins, GCS <10, congestion hemorrhage, large thrombus burden, deterioration despite anticoagulation), then as early as possible
- in cases of large hemorrhagic infarctions and impending herniation, decompressive craniectomy should be performed as early as possible without removal of hematoma or infarcted tissue
- Smoking cessation! Discontinue estrogen-containing contraceptives
- Duration of OAC 3–6 months (except in case of progressive thrombosis in follow-up MRI or known thrombophilia)
- Usually examination for coagulation disorders after stopping OAC

Therap. heparinization unfractionated heparin

- complete baseline coagulation status before start of therapeutic heparinization**
- if baseline aPTT is abnormal (normal: 26–37sec) or in case of extensive thrombosis, consult a hematologist and control anti-factor-Xa-activity (aim 0.3–0.6 U/ml)
- usual aPTT aim: 1.5–2.5x baseline aPTT
- strictly check thrombocytes every 2 days during the course of therapy (HIT? => 4Ts score)

The following dosage scheme is for patients at the Inselspital with low bleeding risk. Depending on infarct size, the dosage should be reduced individually.

Therapy start		Bolus 60–70 U/kg (max. 5000U) i.v. continuously 12–15 U/kg/h (max. 1000 U/h)	Re-evaluation after 6h
Dose adaption depending on aPTT and Anti-Xa			
aPTT	Anti-Xa		
< 35 sec	< 0.2 U/ml	Bolus 40 U/kg Increase infusion rate by 3 U/kg/h	Re-evaluation after 6h
36–45 sec	0.2–0.29 U/ml	No bolus, increase infusion rate by 1.5 U/kg/h	Re-evaluation after 6h
46–70 sec	0.3–0.7 U/ml	No change	Re-evaluation after 6h, then 1x/day
71–90 sec	0.71–1.0 U/ml	Reduce infusion rate by 1.5 U/kg/h	Re-evaluation after 6h
> 90 sec	> 1.0 U/ml	Pause infusion for 1 h then reduce by 2–3U/kg/h (if aPTT >200sec pause infusion for 2h)	Re-evaluation after 6h




Secondary prevention

Etiology	First stroke	Re-Stroke → always repeat or escalate examinations for etiology
no reason determined (specially no cardiac embolism source, no symptomatic stenosis)	ASS 100mg or Clopidogrel 75mg or ASS+Dipyridamole Ticagrelor (Brilique®) in case of intolerance to the other agents	Change to Clopidogrel 75mg or ASS+Dipyridamole Ticagrelor (Brilique®) in case of intolerance to the other agents
	Initial therapy: in case of high-risk TIA (ABCD2>3 points) or minor stroke within 24h (NIHSS < 6, small infarct core): 3 weeks of ASS 100mg p.o. (initial ASA 250 mg i.v.) + Clopidogrel 75mg (loading dose 600 mg) provided there is no hemorrhagic transformation and no individually increased risk of bleeding	
	If additionally CHD, peripheral arterial occlusive disease or asymptomatic carotid artery stenosis: rivaroxaban (Xarelto®) 2x2.5mg + ASA 100mg/d instead of aspirin monotherapy, initiate after 3-4 weeks	
valvular AF (Def: AF with rheumatic mitral stenosis)	OAC INR 2-3	1. optimize dosage if necessary 2. consider OAC INR 2.5-3.5 3. consider OAC + ASS 100mg
symptomatic extracranial carotid stenosis	> 50% degree of stenosis: CEA/CAS < 50% with radiologically proven plaque rupture: individual + statin at high dose	< 50% stenosis with radiologically proven plaque rupture: consider CEA/CAS
symptomatic extracranial vertebral artery stenosis	ASS 100mg + 4 weeks Clopidogrel 75mg + statin at high dose Contralateral hypoplasia: consider stenting	Consider stenting if already under best medical treatment, otherwise longer-term DAPT
symptomatic intracranial stenosis	ASS 100mg + Clopidogrel 75mg for 3 months, then monotherapy + statin at high dose	ASS 100mg + Clopidogrel 75mg (duration individually) + statin at high dose + consider stenting if stroke under best medical treatment, argument pro stent: hemodynamic infarcts
Non-valvular AF	DOAC 1st choice; Occurrence under sufficient or insufficient OAC: - Clarify compliance and correct intake (take RIV with meals); switch VKA to DOAC - In case of AF diagnosis in the last year, rhythmological consultation and referral to rhythmology for evaluation of rhythm control - Search for competing, non-cardioembolic causes (e.g. carotid stenosis) - No additional ASA in case of occurrence under DOAC except in the short term for symptomatic arteriosclerotic stenoses! - Evaluate LAAO if no other cause (ELAPSE trial)	
Instructions for the initiation of antiplatelet aggregation therapy after ischemic stroke		
- With conservative therapy: immediately — loading dose of antiplatelet agents once at the start of treatment: aspirin 250 mg, clopidogrel 300–600 mg, ticagrelor 180 mg. Exception: large hemorrhagic transformation or large demarcated infarct (e.g., >2/3 of the MCA, PCA, or PICA territory) - After IVT/EVT, bridging, urokinase i.a.: after ruling out bleeding on follow-up MRI/CT after 24 hours - Impending cerebral edema/planned craniotomy: do not administer antiplatelet agents		
Instructions for the earliest initiation of (D)OAC after ischemic stroke		
Caution: assumes exclusion of parenchymal hemorrhage (type 2) & endocarditis, cave sensitivity MRI >> CT TIA/small to moderate infarcts (see right): Onset <48h, possibly later with basal ganglia involvement Large infarcts (see next page): Start d6, if necessary follow-up CT to rule out bleeding - No bridging therapy with platelet aggregation inhibitors - When changing therapy, consider “transient dual therapy” due to delayed loss of effect of previous medication (depending on T1/2) - Highly embolic source of embolism (e.g. mechanical heart valve): immediate start of (possibly sub-) therapeutic heparinization if necessary, except in the case of very large infarction/bleeding - In case of relevant hemorrhage (PH1, PH2) in the follow-up imaging, usually start after 10-14d		

Secondary prevention special situations

Myocardial infarction (sub)acute
- consider DOAC application for 3 months also without thrombus finding, esp. with embolic infarct distribution - stenting in patients with (D)OAC indication → (D)OAC + clopidogrel (consider DOAC low dose in large infarctions), triple therapy in acute stroke only in exceptional cases (esp. in-stent-thrombosis, stent main stem) If AF is indication for (D)OAC: consider atrial appendage closure, afterwards only dual antiplatelet therapy STEMI: Coro immediately; NSTEMI: Coro as soon as clopidogrel + ASS or (D)OAC + clopidogrel is possible (depending on indication); Coro immediately in case of severe arrhythmia, hemodynamic instability, persistent pain
Detection of AF or atrial thrombus in patients taking aspirin + clopidogrel due to coronary stent
DOAC long-term therapy + usually 1 year clopidogrel; during dual therapy consider (transient) DOAC low dose depending on infarct sized
Intracardial thrombus
Ventricular: (D)OAC for 3 months, then control TEE and consider change to antiplatelet therapy Atrial appendage thrombus: DOAC therapy life long also without proven AF
Symptomatic stenosis
see previous page
Coronary heart disease or peripheral arterial occlusive disease + high risk for ischemic events
Consider Rivaroxaban 2x2.5mg + ASS 100mg/d
Severe heart failure with severe hypokinesia/akinesia
No DOAC except in case of intra cardiac thrombus (bleeding outweighs benefit). DOAC can be considered for ESUS with restricted EF or regional wall motion disorders.
Infectious Endocarditis
No antiplatelet therapy/heparin/(D)OAC; if valvular replacement is indicated, early operation seems to be beneficial
Pulmonary embolism
DOAC, start depends on infarct size; duration: 6 months in case of unequivocal provocative factors (surgery, immobilization >48h, plaster cast on leg), otherwise long-term therapy; PFO occlusion in case of long-term DOAC therapy not indicated, otherwise PFO closure also with PASCAL „unlikely“
Paraneoplastic Coagulopathy
LMWH therapeutic dosage (2x/d, not 1x/d) or Edoxaban or Rivaroxaban or Apixaban




Covert cerebrovascular disease / brain infarction

- most frequent incidental finding in CT/MRI (no TIA or stroke suspicious episodes in medical history)
- prevalence dependent on cardiovascular risk profile and age (~30% in people at age 70)
- increased stroke risk and severity, risk for dementia, depression and subclinical deficits

Definition by MRI

- acute or subacute ischemia (see A, e.g. acute diffusion lesion with signal decrease in ADC and without symptoms and without other explanation)
- chronic ischemia:
 - T2/FLAIR hyperintense lesion, T1 hypointense lesion non-lacunar (see B)
 - cerebellar or supratentorial cortical, or
 - supratentorial subcortical >3mm with location in deep gray matter and without other explanation
 - lacunar lesion (see C): ≥3mm, not corresponding to enlarged perivascular space



Definition by CT

- cortical defect zone or lacunar lesion

Incidental SVD/leukoencephalopathy:
incidentally discovered cerebrovascular SVD significantly above the age norm should also lead to cardiovascular work-up and counselling with the aim of optimally controlling the cardiovascular risk factors.



Diagnostics

- screen for vascular risk factors and obtain a comprehensive history of previous cardioaortic interventions
- complete vessel imaging if not already done with initial imaging
- pulse palpation, 12-channel ECG, at least 72h ECG monitoring
- TTE/TEE

Therapy

- optimal risk factor control
- ASS with consideration of risk/benefit profile, other indication for antithrombotic treatment ?
- treatment of blood pressure is the same as in secondary prevention guidelines
- consider treatment of carotid artery stenosis > 60% of the affected vessel after consideration of risk/benefit profile, in case of
 - acute ischemia, or
 - multiple chronic ischemia in the corresponding vessel territory

Direct oral anticoagulants (DOAC)

- indicated in strokes with evidence of non-valvular AF
- in cerebral venous thrombosis and dissection: phenprocoumon/acenocoumarol or dabigatran
- **not recommended** in anti-phospholipid-antibody syndrome or valvular AF (valvular: rheumatic mitral stenosis)
- in case of known elevated GI bleeding risk: preferable lower doses of DOAC especially in patients > 75 years

	Factor II-inhibitor	Factor X-inhibitors		
	Dabigatran (Pradaxa®)	Apixaban (Eliquis®)	Rivaroxaban (Xarelto®)	Edoxaban (Lixiana®)
General information	CI: Child-Pugh A-C	CI: Child-Pugh C	CI: Child-Pugh B+C	CI: Child-Pugh C
Dose if CrCl ≥ 50 ml/min	2 x 150mg (≥ 80 years: 2x110mg)	2 x 5mg	1 x 20mg	1 x 60mg (1 x 30mg if bw < 60kg)
Dose if CrCl 30-49 ml/min	2 x 110mg	(2 x 2.5mg if two of the following criteria are fulfilled: ≥80 years, ≤60kg, creatinine ≥ 133 µmol/l)	1 x 15mg	1 x 30mg
Dose if CrCl 15-29 ml/min	contraindicated		1 x 15mg, control of plasma coagulation recommended	1 x 30mg
Dose if CrCl <15 ml/min	contraindicated	not recommended	contraindicated	not recommended
Inductors (effect diminished) (bold print: contraindication)	Rifampicin, St John's wort, carbamazepine	Rifampicin (edoxaban: dosage reduction not necessary), phenytoin, carbamazepine, phenobarbital, St John's wort		
Inhibitors (effect enhanced) (bold print: contraindication)	Verapamil, ketoconazole, itraconazole, voriconazole, HIVprotease inhibitors, quinidine, dronedarone, cyclosporine, tacrolimus, amiodarone	Verapamil, ketoconazole, itraconazole, voriconazole, posaconazole HIV-protease inhibitors		
T_{1/2}	12-17h	9-14h	5-9h	10-14h
Set off time before surgery (in agreement with surgeon)	24h up to 72h in case of large operations 4d with CrCl < 50ml/min	24h 48h in case of high bleeding risk, renal failure, elderly patients	24h 48h in case of high bleeding risk, renal failure, elderly patients	24h before 48h in case of high bleeding risk, renal failure, elderly patients

Risk factors

Responsible for 9/10 Strokes	Responsible for 4/5 Strokes	Hypertension (>140/90 mmHg)
		Lack of physical activity (< 150min/week moderate or <75 min intensive exercise)
		Overweight (BMI >25, abdominal girth >m:94cm/f:88 cm)
		Unhealthy diet
		Dyslipidemia
		Smoking (incl. pipe, cigars)
		Psychosocial stress
		Alcohol abuse (> 30 drinks/month; f>15g/d, m>30g/d)
		Diabetes mellitus (fasting blood sugar ≥7mmol/l, HbA1c ≥ 6.5%); impaired fasting glucose: 5.6-6.9mmol/l
		Family history (m <55 years, f<65 years)
		Pre-stroke/TIA
		Sleep related breathing disorders
		Chronic renal failure
		Migraine with aura (at least 2 auras in a lifetime)
		Pregnancy
		Atrial tachycardia
		Increased variability in blood pressure
		Cardiac wall motion abnormalities
		Contraception
		Hormone replacement therapy
		Acute infection (esp. influenza)
		Depression

Risk stratification

Risk	Criteria	SCORE2 risk chart
Very high risk	- Previous vascular event: cerebral stroke, myocardial infarction, symptomatic peripheral arterial occlusive disease - Detection of atherosclerotic plaques, silent ischemia - Previous revascularization of an artery - Diabetic patients with end-organ damage (e.g., microalbuminuria) or ≥three major risk factors or disease duration >20 years - Severe renal insufficiency (GFR<30 ml/min./m²) - Familial dyslipidemia with a risk factor	>10%/10 years
High risk	1 poorly controlled risk factor (e.g., LDL cholesterol >4 mmol/L, triglycerides >8 mmol/L, or BP ≥180/110 mmHg) - Familial dyslipidemia without poorly controlled risk factors - Diabetic patients ≥10 years of disease duration, without end-organ damage and without additional risk factors - Moderate renal insufficiency (GFR 30–59 ml/min./m²)	5–10%/10 years
Moderate risk	Young diabetics (if type 1 diabetes <35 years, if type 2 diabetes <50 years) with a duration of disease <10 years, without other risk factors	1–5%/10 years
Low risk	No criteria met	<1%/10 years

Arterial hypertension

Stepwise drug treatment: Typically, target value after ischemic stroke <130/80 mmHg			
- Monotherapy for: patients ≥85 years of age; at least moderate frailty, symptomatic orthostatic hypotension, and baseline BP 120–139/70–89 mmHg - Otherwise, dual combination therapy, first choice (ACE inhibitor or ARB plus calcium antagonist and/or diuretic → check after 1-3 months) - If blood pressure is not controlled: low-dose triple combination therapy (ACE inhibitor or ARB plus calcium antagonist and diuretic) → check after 1–3 months - If BP is still not controlled: maximum tolerated triple combination therapy. If BP remains uncontrolled even after this, apparent resistant hypertension is present. In this case, secondary causes should be ruled out (see below, referral to hypertension clinic if necessary), compliance should be checked, and spironolactone should be added.			
Notes			
- At each stage, beta-blockers can be added if there are compelling indications (e.g., angina pectoris, postmyocardial infarction, systolic heart failure, or for frequency control) - Blood pressure variability significantly increases stroke risk → calcium antagonists - Caution is needed with vascular occlusions and/or high-grade stenoses (consider higher target values/slower titration) - GFR <30 ml/min: Thiazide diuretics are not effective			
Secondary arterial hypertension			
In the case of resistance to therapy (especially in patients <75 years, normal weight, healthy lifestyle, absence of diabetes mellitus and/or organ damage due to vascular risk factors) Causes: sleep-associated respiratory failure, primary hyperaldosteronism, chronic renal failure, pheochromocytoma, fibromuscular dysplasia, coarctation of the aorta, Cushing's syndrome, Hyperparathyroidism, medications (oral contraceptives, sympathomimetic mucosal decongestant therapy, NSAIDs, cyclosporine, erythropoietin, chronic steroid therapy, chemotherapeutic agents), drugs (cocaine, amphetamines, anabolic steroids), other substances (licorice)			
	Systolic	Diastolic	Recommendations
Optimal	<120	<80	-
Normal	120–129	80–84	-
High-normal	130–139	85–89	< 65 years, low/moderate risk: primarily non-drug therapy < 65 years, high/very high risk: drug + non-drug therapy ≥ 65 years: primarily non-drug therapy
AH grade 1	140–159	90–99	<80 years, low/moderate risk: Combined non-drug (focus) and drug therapy < 80 years high/very high risk: intensive drug and non-drug measures ≥ 80 years: primarily non-drug measures
AH grade 2	160–179	100–109	Combined non-drug and drug therapy (>80 years especially with good AZ)
AH grade 3	≥ 180	≥ 110	Combined non-drug and drug therapy (>80 years especially with good AZ)
Isolated systolic AH	> 140	and < 90	Non-drug therapy + regular check-ups

Dyslipidemia


CAVE Important note on individualized therapy

The treatment of dyslipidemia and the application of the scheme below requires a **correct pre-selection of patients. Patients without arteriosclerosis i.e. with dissection, confirmed paradoxical embolization, iatrogenic strokes, etc. do NOT require mandatory statin therapy.** In these cases, the indication should be based on the criteria for primary prevention (not listed here).

General

- For every 1 mmol/L increase in total cholesterol, relative risk of ischemic cerebral infarction increases by 25%
- In cerebral infarction associated with atheromatosis, achievement of a target LDL cholesterol <1.8 mmol/L shows a better prognosis than a target of 2.3–2.8 mmol/L
- For symptomatic/multiple stenoses/significant atheromatosis of the aorta: usually a high dosage (e.g. atorvastatin 80 mg), target LDL value: < 1.4 mmol/L
- *Rosuvastatin, Pitavastatin, Atorvastatin **Evolocumab, Alirocumab, Inclisiran

See AGLA
Pocketguide
Prävention der
Atherosklerose
2023



Vascular risk:	Low	Moderate	High or arteriosclerosis detected	Very high or symptomatic stenosis
LDL	Target <3mmol/L	Target <2.6mmol/L	Reduction of baseline value by >50%. Target <1.8 mmol/L	Reduction of baseline value by >50%. Target <1.4 mmol/L
Non-HDL cholesterol (TG-HDL)		Target <3.4mmol/L	Target <2.6mmol/L	Target <2.2mmol/L
TG	Target <1.7 mmol/L			

Diabetes mellitus

General

- Recommended target value of HbA1c <7%
- Avoid hypoglycaemia, as it increases vascular risk
- Target value of blood pressure in patients with diabetes: <65 yr <130/80 mmHg, >65 yr <140/80 mmHg
- in case of high/very high risk (see below): aspirin 100 mg/day possibly already part of primary prophylaxis

Risk stratification in patients with diabetes

Very high risk: Diabetes mellitus + vascular clinical event or organ damage that has already occurred, or >3 other vascular risk factors, or type 1 diabetes mellitus with a duration of >20 years
High risk: Duration of disease >10 years without organ damage but with at least one additional vascular risk factor
Moderate risk: Young patient with diabetes mellitus type 1, and <50 yr for patient with diabetes mellitus type 2, with short duration of disease (<10 years) and no other vascular risk factors


Non-medical: weight reduction, Mediterranean diet, physical activity, smoking cessation

Medications

Metformin additionally for (very) high cv risk if required for glucose control


LDL targets for diabetes
 - Very high risk: <1.4mmol/L
 - high risk: <1.8mmol/L
 - moderate risk: <2.6mmol/L

Finerenone Kerendia® for impaired renal function to delay progression.
GLP1-RA for overweight patients even if no other indication (DM2)




Risk stratification for DM2 according to presence of atherosclerotic cardiovascular disease (ASCVD), target organ damage and 10-year risk; see Marx et al. EHJ 2023

see Goldenberg et al. Stroke 2022



Diet

- **Recommendation:** consumption of fresh fruits, vegetables (the more the better, i.e. ≥ 3 servings/day). ≥ 5 servings: risk reduction 26% (RR 0.74; 95% CI 0.69–0.79; $p < 0.0001$). 3–5 servings: risk reduction 11% (RR, 0.89; 95% CI 0.83–0.97; $p = 0.005$).
- Beneficial effect of **Mediterranean diet** (consumption of legumes, whole grains, low-fat dairy products, fish, unsaturated fatty acids e.g. olive oil): risk reduction 44%
- Beneficial effect of **DASH diet** (low-fat diet rich in minerals, vitamins and whole grains): risk reduction 25%
- **Salt consumption** < 5 g/day; reduction by 1 teaspoon/day: risk reduction 30%
- Consumption of **coffee** has probably a beneficial effect (U-shaped curve for association with risk of stroke, max. 3–4 cups/day associated with 17% risk reduction)
- Consumption of **tea** (green and black) has probably a beneficial effect (risk reduction of 13% with intake of 3 cups/day)
- Consumption of dark **chocolate** has probably a beneficial effect
- Max. **alcohol** consumption < 14 units/week for men and < 8 units for women (1 unit = 250 ml beer or 125 ml wine); avoid binge drinking.
- Avoid drinks with refined sweeteners
- Unfavourable effect of saturated fatty acids
- Questionable or very small unfavourable effect of red meat



Adapted according to GBD 2017 Diet Collaborators. Lancet

Body weight

- Target BMI < 20 – 25 kg/m^2
- Target abdominal circumference: men: < 94 cm, women: < 80 cm
- Stroke mortality increases by 40% per 5 kg/m^2 increase in BMI

Smoking

- Smoking cessation: medical counselling, self-help interventions, group behavioural therapy, telephone counselling, medications (e.g., vareniclin, alternatively bupropion, clonidine) are effective
- For addresses of advisory centres see <https://stopsmoking.ch/>

Ambulatory support programme

- Consider enrolling patients into ambulatory support programmes for secondary prevention

Chronic coronary heart disease and heart failure

Chronic coronary heart disease:

- ASA 100mg/d + rivaroxaban 2.5mg 2x/d if no increased risk of bleeding
- GLP1-RA in CHD and type 2 diabetes
- SGLT2 inhibitors in LVEF $< 41\%$ even without DM2
- no long-term beta-blocker therapy

Heart failure (reduced EF): sacubitril/valsartan (Entresto), beta-blockers (carvedilol), spironolactone, SGLT2i

Heart failure (normal EF): diuretics (if volume overload), SGLT2i for LVEF $< 41\%$ even without DM2, spironolactone

Physical inactivity

Physical activity has a beneficial effect on vascular risk factors, has antidepressant effects and promotes smoking cessation


Recommendation: at least 20–60 min. exercise on 3–5/days per week of at least moderate intensity (e.g. walking, jogging, swimming, cycling)
(specific recommendation for high blood pressure: 60–90 min./week, weight reduction: 225–420 min./week, diabetes: 150 min./week)

- 8% of all deaths are related to physical inactivity
- 28% reduction in relative risk of stroke, myocardial infarction and vascular fatality with physical activity (compared to 22% with ASA, 21% with statins, and 21% with antihypertensives)
- Stroke risk reduced by 30% with > 40 min of moderate/high intensity activity 3–4x/week

Sleep apnoea syndrome

- Screening with respiratory polygraphy
- Treatment with CPAP/APAP/ASV indicated with
 1. AHI ≥ 30 /h: send for PAP after discharge
 2. AHI 10–29.9/h: reevaluate PAP after 3 months
 3. AHI ≤ 10 /h: only send for PAP if Epworth SS ≥ 10 or NoAS ≥ 8

Non-traumatic intracerebral hemorrhage (ICH)




Reversion/substitution scheme

Anticoagulant	Treatment	Notes
Alteplase/ tenecteplase	See also page 14 → Fibrinogen (Haemocomplettan P) or prothrombin complex concentrate (Prothromplex®) after consultation with hematology → Tranexamic acid (Tranexam OrPha) i.v. 1000 mg over 10 min → blood pressure target ≤ 140/90 mmHg	See page 14
Marcoumar® / Sintrom® und INR > 1.3	Prothrombin complex concentrate (Prothromplex®): 30 IU/kg KG → check INR (point-of-care) after 15 minutes and re-dose if necessary Vitamin K (Konaktion MM®): 10mg i.v., depending on INR over time; onset of effect after approximately 4–6 hours	Repeat prothrombin complex concentrate in case of insufficient INR decrease after 15min. Then INR at least 1x/d (and if necessary repeat Konaktion)
Heparin UFH	Protamine sulfate (Protamin®): If Heparin was stopped ≤1h or anti-Xa activity ≥ 0.35: 1000 IU i.v. (1ml) per 1000 IU heparin given during the last 3 hours (max. 5000 IU); If Heparin was stopped 1–3h before or anti-Xa activity is between 0.15–0.35: 500 E i.v. (0.5ml) per 1000 IU heparin given	Involve haematology; beware of contraindications!
Heparin LMWH	Protamine sulfate Protamin®: Last therapeutic dosage given ≤8h or anti-Xa activity ≥ 0.5: 5000 IU protamine sulfate Last therapeutic dosage given 8–12h or anti-Xa activity 0.3–0.5: 2500 IU protamine sulfate	Involve haematology; beware of contraindications!
Xa-Inhibitors Apixaban/ Edoxaban/ Rivaroxaban/	Andexanet alfa (Ondexxya™) Criteria: Symptom onset <6 hours, NIHSS <36, GCS >6, ICH volume 1–60 mL, last DOAC dose <15 hours or if unknown, plasma level >100 ng/mL. Exclusions: Thrombotic event in the last 14 days, mRS >3. → use rather the low dose: 400 mg bolus (30 mg/min), continuous infusion 4 mg/min over 120 minutes (480 mg) = 5 vials. If the criteria are not met, do not administer Andexanet and also no PCC (no efficacy in DOAC bleeding)	Determination of substancespecific anti-Xa activity upon presentation Caution: increased risk of cerebrovascular events and heart attack with Andexanet
Ila-Inhibitor Dabigatran	Idarucizumab (Praxbind® 2x2.5g) available as a specific antidote Criteria: Symptom onset <6 hours, NIHSS <36, GCS >6, ICH volume 1–60 mL, last DOAC dose <15 hours or if unknown, plasma level >100 ng/mL, prestroke mRS <3 If the criteria are not met, do not administer Praxbind® and also NO PCC (no efficacy in DOAC bleeding)	Obtain thrombin time and antilla activity/drug levels on admission
Antiplatelet	No specific treatment	thrombocyte infusion potentially harmful
Thrombocyto- penia	Severe thrombocytopenia(<70.000/ml)/severe platelet dysfunction: platelet concentrate	
Hemophilia or factor deficiency	Substitution of the coagulation factor after consultation with haematology	
	Note: NO efficacy in studies: steroids, tranexamic acid, activated factor VIIa.	

Diagnostic algorithm for ICH

- 1) **Primary imaging in ED with CT or MRI** always with **angiography** – suspicion of macrovascular bleeding cause (AVM, aneurysm, bleeding in SVT, etc.)?
- 2) **Indication for invasive Angio** (IADSA): interdisciplinary decision neuroradiology, neurosurgery, neurology, structured decision pathway is helpful (see below)
- 3) **SVD – Small vessel disease**: signs of microangiopathy in CT/MRI (leucencephalopathy, microbleeds)
- 4) **Follow-up imaging after 24h for evaluation of hematoma expansion** (prognostic marker and quality control)



Wilson et al, European Stroke Journal 2017

Re-initiation of anticoagulatory medication after ICH

- **Heparin for prevention of thrombosis**: LMWH (e.g. Enoxaparin) after follow up imaging after 24h or pneumatic compression stockings
- **Antiplatelet monotherapy ASS/Clopidogrel**: depending on individual risk after follow up imaging earliest 7d after ICH
- **Phenprocoumon for mechanical heart valve**: earliest 7d after ICH in case of high embolic risk, otherwise 14d
- (D)OAC for atrial fibrillation: individual decision, consider atrial appendage closure

Microbleeds

- differential diagnosis of incidental „microbleeds“ findings in SWI: prior extracorporeal bypass (ECC), ECMO, thrombus, metastasis, microangiopathy, vasculitis, cerebral amyloid angiopathy
- most frequent origin: microangiopathy
- consider cerebral amyloid angiopathy (see below)

Microbleeds & Antiplatelet therapy/(D)OAC

- Effect of secondary prophylaxis with antiplatelet therapy and (D)OAC outweighs bleeding risk
- Bleeding risk and risk for ischemia rises with number of microbleeds, but risk for ischemia remains higher

Cerebral amyloid angiopathy (CAA)

- Progressive dementia
- Frequently one or multiple small ischemic strokes or microbleeds in follow up images
- Frequently concomitant white matter hyperintensities

MRI: [modified Boston criteria 1.5](#) for age >55 y

- Possible CAA
- Singular bleeding lobar, cortical or cortical-subcortical localisation (cerebellar allowed)
- or focal or disseminated superficial siderosis
- exclusion of other causes of ICB

Probable CAA

- multiple bleedings lobar, cortical or cortical-subcortical localisation (cerebellar allowed)
- or singular, cortical-subcortical bleeding and focal or disseminated superficial siderosis
- exclusion of other causes of ICB

Definitive CAA

- Autoptic proven

Cave: use Boston criteria only if patient has one of the following:


- cognitive decline
- cerebral hemorrhage
- “spells”

NOT as screening for all MRIs in asymptomatic patients


[Boston criteria 2.0](#): are more sensitive, but less specific (possible overdiagnosis)

CT: Edinburgh criteria

Finger-like projections (FLP): elongated extension from the hematoma (longer than wide)
Subarachnoid hemorrhage (SAH): extension of the bleeding in subarachnoid space



Hostettler, Seiffge & Werring, Expert Rev Neuroth 2019



Amyloid angiopathy & Antiplatelet therapy/(D)OAC


- with probable CAA: stop antiplatelet therapy/(D)OAC ONLY IF no other explanation for CMBs and CAA clinically symptomatic, see above
- consider atrial appendage closure in case of atrial fibrillation
- in case of mechanical valves individual decision (reports of low embolic risk without OAC in some types of valves)

CAA-related Inflammation (CAA-ri)

Diagnostic criteria

Possible CAA-ri (if all 5 criteria are met)


1. Age ≥ 40 years
2. Presence of at least one clinical symptom not directly associated with ICH, consisting of headache, impaired consciousness, behavioural abnormalities, focal neurological symptoms, epileptic seizures
3. MRI showing evidence of hyperintensities in the medullary canal extending to the surrounding subcortical medullary canal
4. Presence of at least one of the following corticosubcortical hemorrhages: cerebral macrohemorrhage, cerebral microhemorrhage, cortical superficial siderosis
5. Exclusion of neoplasia, infection, or other genesis.



Right occipital asymmetric FLAIR hyperintensity + microbleeds

Likely CAA-ri

1. Age ≥ 40 years
2. Presence of at least one clinical symptom not directly associated with ICH, consisting of headache, impaired consciousness, behavioural abnormalities, focal neurological symptoms, epileptic seizures
3. MRI demonstrating unifocal or multifocal hyperintensities in the medullary (corticosubcortical or deep medullary) bed that are asymmetric and extend to the surrounding subcortical medullary bed (and the asymmetry is not a result of old ICH)
4. Presence of at least one of the following corticosubcortical hemorrhages: cerebral macrohemorrhage, cerebral microhemorrhage, cortical superficial siderosis
5. Exclusion of neoplasia, infection, or other genesis




2 months after steroid therapy

Therapy

1. **Steroid therapy**
 - High-dose therapy with solumedrol 1g/d for 3d, followed by
 - Steroid maintenance therapy prednisolone 1mg/kg bw (under gastric and osteoporosis protection).
2. **Additional immunosuppression, insufficient evidence as to which is preferable**
 - Cyclophosphamide
 - Mycophenolate mofetil
 - Rituximab
3. **Early control with ICH consultant after 4–6 weeks incl. MRI**

Algorithm Convexity SAH



	RCVS	PRES	CVST	CAA
Age	<60	<60	<60	≥ 60
Headache	frequent	frequent	frequent	Rare
Confusion / consciousness alteration	rather rare	frequent	rather rare	rather rare
Seizures	rather rare	frequent	~ 1/3	rather rare
Transient Episodes with focal neurological deficits	rather rare	Unusual	rather rare	frequent
Nausea / Vomiting	rather rare	rather rare	rather rare	Unusual
Visual symptoms	frequent	frequent	rather rare	Unusual
Diagnostic testing				
CT/A/V & MRI/A/V	Caliber irregularities	Typical changes	Detection of venous thrombosis and infarction/bleeding	Modified Boston Criteria
EEG	usually normal	Frequently altered	usually normal	usually normal
CSF (in addition to Xanthochromia)	Frequently normal	Protein increase, pleocytosis occurs	Normal except for congestive infarction or hemorrhage	frequently normal

Supported by

Monogenic neurovascular diseases

Syndrome/	Gen, Inheritance	Symptoms	Imaging
CADASIL	NOTCH3, aut.-dom.	Migraine, cognitive problems, depression, epileptic seizures, recurrent stroke ischemic > hemorrhagic	Hyperintensity, emphasized anterior temporal lobe and caps. ext., lacunar infarcts
CARASIL	HTRA1, aut.-rec.	Spasticity, cognitive problems, alopecia, back pain, spondylosis, recurrent stroke ischemic > hemorrhagic	WMH
Fabry	GLA X-chrom.	Episodes of pain in hands and feet, angiokeratomas, corneal opacity, involvement of kidneys, heart	
RVCL / HERNIS	TREX1 aut.-dom.	Loss of vision, cognitive problems, stroke-like episodes, liver and kidney dysfunction, retinal microangiopathy	Dominantly ischemic SVD
MELAS	Mitochondrial	Stroke-like episodes, migraine, muscle weakness, epil. Seizures, short stature, hearing loss, episodic vomiting, diabetes, cardiomyopathy, retinitis	DWI-impaired, but NOT ADC attenuated, territory-spanning lesions, atrophy, basal ganglia calcification
Ehlers-Danlos IV	COL3A1, aut.-dom.	Hypermobility of joints, thin skin and tendency to bruises, intestinal and uterine ruptures, subluxations and pain, muscle cramps	Cerebral aneurysms and/or spontaneous arterial dissections
COL4A- and COL4A2 associated angiopathy	COL4A1, COL4A2 aut.-dom.	Brain hemorrhages, epileptic seizures, migraine, ophthalmologic anomalies, kidney, heart, muscle involvement, possibly cognitive symptoms	Hemorrhagic SVD, aneurysms, extensive WMH, porencephaly
DADA2	ADA2 aut.-rec.	Polyarteritis nodosa, small vessel vasculitis, recurrent fever, livedo racemosa childhood, hepatosplenomegaly, hematologic abnormalities, immune dysregulation, neurologic deficits	Lacunae and hematoma. SVD, spinal infarcts, intracranial aneurysms, inflammatory perivascular tissue in the basal and peripontine cisterns.
Fam. Moya-Moya	ACTA2, MTCPI, RNF213, GUCY1A3 aut.-rez./dom.	Headache, hypoperfusion, telangiectasia, cognitive impairment, epilept. seizures	(bilateral) stenosis ICA-T/ M1, collaterals ("cloud")
Fam. Hemiplegic migraine	CACNA1A, ATP1A2, SCN1A1 aut.-dom.	Migraine with aura and motor paresis/hemiplegia	Primarily ischemic SVD
Sickle cell disease	HBB aut.-rec.	Anemia, pain attacks, infections, lung/kidney/spleen manifestations, African descent	Moyamoya-like
Marfan	FBN1 aut.-dom.	Lens dislocation, cataract, myopia, arthritis, large habitus, pectus excavatum, dural ectasia	Aortic aneurysm/dissection, Carotid artery dissection

General Remarks:

- Genetic testing only if clinical or imaging findings are suggestive and the patient wishes it (declaration of consent with signature)
- M. Fabry by blood drop test (stroke unit)
- Cost approval by health insurance required in advance, blood sample can already be taken
- If clinical or imaging findings are compatible with several syndromes, direct panel testing.
- If clinical/imaging findings are highly suggestive of a syndrome, single gene sequencing first
- Further phenotypes and manifestations are described [here \(SVD\)](#) and [here \(also non-SVD\)](#)

Driving capacity & cerebrovascular diseases

Non-binding recommendations according to [DGN/DSG position paper](#), period given in months, for further recommendations (SAB, AVM, cavernomas, vasculitis see link).
Recommendations for period only if somatically and neurocognitively able to drive!

	Private driving	Other categories
TIA, low risk profile	1	3
TIA, high risk profile	3	6
TIA, ICAD	6	No
Ischemic stroke, low risk e.g. after CAS/CEA, cryptogenic stroke, AF with DOAC, SVD	1	3
Ischemic stroke, high risk, e.g. best medical management of symptomatic stenosis, AF without anticoagulation, dissections, high vascular risk profile	3	6
ICH due to deep perforator arteriopathy, BP well controlled	1	3
ICH due to CAA or symptomatic ICH with more than 5 asymptomatic microbleeds or superficial siderosis	No	No

Life after Stroke - Checklist

Complaints

Fatigue/sleepiness, sleep disorders, headache, pain, emotional disorders, depression, anxiety, memory/concentration disorders, dizziness, unsteady gait, paralysis, visual disorders, swallowing disorders, incontinence, sexuality
-> Which of the above are particularly disabling? Treatment suggestion?

Spasticity

Documentation with [modified Ashworth scale](#)
Focal: Botox; **generalized:** Baclofen, tizanidine, tolperisone, clonazepam

Social life

Friends, independence (bathing/showering, eating, mobility, stairs, getting dressed), hobbies, driving a car
-> why social withdrawal? Optimization of mobility, tiredness/mood?

Work

Workload, Insurance, adapted activity?
-> Need advice, social services, consultation with company? Rehab consultation

Prevention

Stop or reduce smoking, (target) weight, physical activity, healthy diet (fruit/vegetables, little salt, little red meat, whole grains)
Blood pressure values, general practitioner checks, sleep hygiene
-> Stop smoking consultation, nutritional advice, handing out prevention booklet

Medication

Compliance, adherence, correct dose, side effects? Which ones?
-> Counseling, medication dosage, reminder, alternative preparations

Therapies

Physiotherapy, Ergotherapy, Speech therapy, Neuropsychological therapy-
Unmet need?
—> ambulatory therapy, interval rehab as an option

Central Retinal Artery Occlusion (CRAO)

GP / first contact

Credit and thanks to Prof. Sven Poli

If suspicion of CRAO/BRAO, immediate referral to a hospital with the possibility of intravenous thrombolysis (notify ophthalmology and neurology in advance)

Ophthalmology — „time is retina“

Acute, painless monocular loss of visual acuity <12h - patient has **top priority**, emergency and time pressure - involve attending immediately!

Symptom onset - determination of symptom onset (time, with wake-up/unclear time window “last normal”), monocular/binocular? Previous amaurosis fugax?

Visual acuity - usually ≤ 0.05 or hand movement (cave: rarely spontaneously reperfused occlusion with improvement)

Finger perimetry (DD hemi/branch occlusion), motility restrictions
RAPD - Relative afferent pupillary deficit in the affected eye?

Funduscopy (in miosis): Embolus? Cherry red spot of the macula? Cilioretinal vessel? Bleeding? Anterior segment of the eye. **Tensio measurement**

Clinical suspicion of **giant cell arteritis?** (temporal arteritis):
Chewing/combing/head pain? B-symptoms? Rheumatologic underlying disease?

In case of **loss of vision <12h** Stroke emergency work-up (MR/CT angiography, stroke laboratory incl. ESR, and start of secondary prophylaxis), always notify attending neurologist, coordinate management with ophtha

Transport - For transfer and handover of the patient to the emergency neurologist within the 4.5 h time window, the patient should, if possible, be taken directly to the ED accompanied by the ophthalmologist (fastest transport option).

ED Neurology

Acute, painless monocular loss of vision <12h - patient has top priority, **emergency and time pressure!**

If a patient presents directly to the ED **within the 4.5 h time window** WITHOUT a prior ophthalmological examination, contact the duty ophthalmologist at the eye clinic at 27367 immediately and organize an ophthalmological examination as quickly as possible (exclusion of critical differential diagnoses such as retinal detachment, vitreous hemorrhage), examination as above

Normal stroke workflow (NIHSS, MRI/CT Priority 1 if <4.5h)

Patients with CRAO or retinal branch occlusion are admitted, diagnosed and treated like patients with ischemic stroke, even if symptoms >4.5h.

Antithrombotic therapy (individual decision on thrombolysis if <3 hours after symptom onset, depending on visual loss/time window/patient preference and only after cMRI/cCT to exclude (sub) acute, hemorrhagic transformed infarcts

Exclude other contraindications, see page contraindications for i.v. thrombolysis

Alternatively, ASA/DAPT if arteriosclerotic etiology suspected

In case of suspected giant cell arteritis (chewing pain, painful on palpation, hardened, possibly pulseless superficial temporal artery, pain when combing hair, B symptoms) no intravenous thrombolysis, if ESR high and possibly elevated CRP, immediate administration of 1g methylprednisolone i.v.; Admission and then: consultation rheumatology, ultrasound of temporal arteries, MRI with dark blood sequences, if necessary biopsy of temporal artery.

Etiology: embolism (cardiac, carotid artery), thrombosis, giant cell arteritis, collagenoses (polyarthritis nodosa, SLE), coagulation tendency (polycythemia, antiphospholipid-AB, oral contraceptives), sickle cell anemia, TPHA

Differential diagnosis: occlusion of the ophthalmic artery, AION, certain lipid storage diseases (e.g. Tay-Sachs) **Organize:** OCT (swelling/washing of inner retinal layers), fluorescein angiography if necessary


Always **admit to stroke** unit if intravenous thrombolysis, cerebral ischemia or carotid stenosis



Always interdisciplinary consultation: admission (ABCD2 score analogous to TIA pathway) Stroke Unit or Ophtha; usually start ASA.


-> **Follow-up** at Ophtha (pressure measurement, documentation of fundus, OCT, visual acuity) or private ophthalmologist if available (during/at the end of hospitalization, otherwise during the first month).

Functional systems

- Motor areas
- Speech areas
- Visual areas
- Sensory areas







Medulla oblongata (Fig. 1-4)


- Anterior spinal artery
- Anterior spinal artery
- Vertebral artery
- Posterior inferior cerebellar a.
- Posterior spinal artery
- Vertebral artery
- Anterior inferior cerebellar a.
- Posterior inferior cerebellar a.

Pons (Fig. 5-8)


- Medial pontine a. of basilar a.; branches of posterior cerebral artery
- Lateral pontine a. of basilar a.
- Lateral pontine a. of basilar a.
- Anterior inferior cerebellar a. (Fig. 8; Superior cerebellar a.)
- Anterior inferior cerebellar a.
- Posterior inferior cerebellar a.
- Superior cerebellar a.

Mesencephalon (Fig. 9-10)

- Central posteromedial a. of posterior cerebral artery
- Collicular and choroidal posterior medial a. of posterior cerebral artery
- Collicular and choroidal posterior medial a. of posterior cerebral a.
- Collicular and choroidal posterior medial a. of posterior cerebral a., superior cerebellar a.
- Superior cerebellar artery



- Anterior cerebral a.
- Middle cerebral a.
- Middle cerebral a., lenticulostriate branches
- Posterior cerebral a.
- Anterior choroidal a.
- Posterior choroidal a. (from P2)
- Anterior communicating artery
- Posterior communicating artery
- Thalamoperforating A. (from P1 or BA; if jointly main trunk: Percheron artery)
- Thalamogeniculate a. (from P2)
- Internal carotid a.



“Close your eyes
He’s a chip off the old block.
Harm set, harm get.”

HUCKLEBERRY
BASEBALL PLAYER

Neurovascular Board / Carotid Board

- For interdisciplinary discussion of neurovascular cases
- Time: _____
- Location: _____
- Registration via: _____

Associated Stroke Units and Neurorehabilitation

Register as early as possible for rehab to avoid a delayed start to rehabilitation!

Contact _____ for rehab screening.

Enter direct contact numbers / mails for your affiliated stroke units and rehab departments below:

Glasgow Coma Scale

Eye opening response	4 Spontaneously 3 To speech 2 To pain 1 No response
Best verbal response	5 Oriented to time, place, and person 4 Confused 3 Inappropriate words 2 Incomprehensible sounds 1 No response
Best motor response	6 Obeys commands 5 Moves to localized pain 4 Flexion withdrawal from pain 3 Abnormal flexion (decorticate) 2 Abnormal extension (decerebrate) 1 No response

CHA₂DS₂-VASc-Score (stroke risk with AF)

Risk factor	Points	(N)	Sum	Risk/year taking Aspirin
Congestive heart failure	1	O A C	0	0%
Hypertension	1		2	2.2%
Age > 75	2		3	3.2%
Diabetes mellitus	1	I F	4	4.8%
Stroke/TIA/thromboembolism	2		5	7.2%
Vascular disease (heart, peripheral)	1	P O I N T	6	9.2%
Age 65-74 years	1		7	11.2%
Woman	1		8	12.2%
			9	

Modified Rankin Scale (mRS)


0	No symptoms at all
1	No significant disability despite symptoms; able to carry out all usual duties and activities
2	Slight disability; unable to carry out all previous activities, but able to look after own affairs
3	Moderate disability, requiring some help, but able to walk without assistance
4	Moderately severe disability; unable to walk without assistance and unable to attend own bodily needs
5	Severe disability; bedridden, incontinent and requiring constant nursing care and attention
6	Dead

NIH Stroke Scale

Points	Category	Explanation
	Level of consciousness	0 Alert 1 Not alert, but arousable by minor stimulation 2 Not alert, requires repeated stimulation to attend. Or, obtunded and requires painful stimuli to make movements 3 Makes only reflexive posturing movements to repeated painful stimuli. Or, they are totally unresponsive
	Orientation anarthria, intubation=1, coma=2	Ask the current month and the patient's age. 0 Answered both questions correctly 1 Answered one correctly 2 Answered neither question correctly or aphasia
	Commands	Ask the patient to open/close the eyes and make a fist/relax the non-paretic hand. 0 Performed both correctly 1 Performed one correctly 2 Performed neither correctly
	Best gaze uncooperative=1, coma=2	0 Normal 1 Partial gaze palsy = Conjugate gaze deviation that can be overcome with voluntary or reflexive activity 2 Forced deviation
	Visual Fields not evaluable=0, neglect=1, coma=3, in case of aphasia, evaluate reaction	0 No visual loss 1 Partial hemianopia 2 Complete hemianopia 3 Bilateral hemianopia
	Facial palsy coma=3	0 Normal 1 Minor paralysis (flattened nasolabial fold or mild asymmetry while smiling) 2 Partial paralysis (total or near total paralysis of lower face) 3 Complete paralysis of upper and lower face
Left:	Motor arm coma=4	0 No drift, remains in position for 10 sec. after an initial dip 1 Jerks or drifts to an intermediate position without encountering support before the full 10 sec. 2 Some effort against gravity. Drifts down before 10 sec. 3 No effort against gravity and the arm falls 4 No Right: voluntary movement
Right:		
Left:	Motor leg coma=4	0 No drift, remains in position for 5 sec. after an initial dip 1 Jerks or drifts to an intermediate position without encountering support before the full 5 sec. 2 Some effort against gravity. Drifts down before 5 sec. 3 No effort against gravity and the leg falls 4 No voluntary movement
Right:		

NIH Stroke Scale Part 2

Points	Category	Explanation
	Limb ataxia coma, aphasia, paralyzed=0	0 Absent 1 Present in one limb 2 Present in two limbs
	Sensory bilateral loss=2, coma=2 aphasia=rather 1	0 Normal 1 Mild to moderate sensory loss, patient feels asymmetry between the two sides but is still aware of being touched 2 Severe or total sensory loss, patient is not aware of being touched on the face, arm, and leg
	Best language Intubated patients should be asked to write, coma=3	0 No aphasia 1 Mild to moderate aphasia; some obvious loss of fluency or facility of comprehension without significant limitation on ideas expressed or form of expression 2 Severe aphasia; all communication is fragmentary; great need for inference, questioning, and guessing by the examiner 3 Mute or global aphasia; globally aphasic patients have no usable speech or auditory comprehension
	Dysarthria coma=2	0 Normal 1 Mild to moderate dysarthria; patient can still be understood 2 Severe dysarthria; patients are either mute or speech is so slurred they cannot be understood out of proportion to any dysphasia that is present
	Extinction and inattention coma=2	0 Absence of neglect 1 Inattention to one modality only (visual, tactile, auditory, spatial, or personal inattention) 2 Profound hemi-inattention or extinction to more than one modality; does not recognize own hand or orients only to one side of space



Distance: 40cm

Visus

Arterial access site complications

Typical complications

Hemorrhagic

- Local hematoma or persistent bleeding at puncture site
- Pseudoaneurysm
- Retroperitoneal bleeding (with high puncture)
- Arteriovenous fistula

Ischemic

- Stenosis or occlusion of the femoral artery (e.g. due to closure device)
- Distal embolism
- Dissection or thrombosis

Key symptoms and warning signs

Hemorrhagic

- Painful, enlarging swelling or discoloration in the groin
- Hypotension, tachycardia, hemoglobin drop
- Flank or back pain (suspicion of retroperitoneal bleeding)
- Systemic dizziness, pallor, cold sweating

Ischemic

- Pain, pallor, pulselessness, paresthesia, paresis, poikilothermia (6 P's)
- Cold limb, delayed capillary refill
- New onset claudication or reduced walking distance

Immediate measures (ABCDE and alerting)

- Stabilize A/B/C (O2, IV lines, fluids, blood pressure monitoring).
- Always immediately inform the responsible neuro-interventionalist (no. 23484).
→ In parallel contact Angiology (endovascular or percutaneous preferred no. 25715).
- In case of active bleeding apply immediate compression (manual or FemoStop).
- In case of active hemodynamically relevant bleeding or critical ischemia: direct transfer to emergency CT (INO B) after consultation.

Diagnostics (prioritized by stability)

Unstable or suspected active bleeding

- Emergency CT (non-contrast, arterial, if needed delayed venous phase to search for leak) of abdomen and pelvis to identify bleeding source. If neurological deterioration additionally non-contrast CT of the head
- Immediate notification of interventional radiology - ad hoc angio (INO B) in case of active bleeding or leak.

Stable

- Duplex ultrasound of the groin (hematoma, pseudoaneurysm, AV fistula, flow).
- Duplex or CT angiography of pelvic and femoral vessels in case of ischemic signs.
- Basic labs: hemoglobin, coagulation (INR, aPTT), platelets, crossmatch, renal function.

Treatment pathway - general principle

- Primary endovascular or percutaneous approach (Angiology): Covered stent, stent graft, balloon tamponade, thrombin injection (pseudoaneurysm), PTA or stent, thrombectomy, fibrin glue, ProGlide or AngioSeal re-intervention.
- Surgery only after exhaustion of endovascular options and after consultation with neuro-interventional radiology.
- Transfusion according to clinical status and labs - stabilize circulation.

Ischemic - specific management

- Heparin bolus (if no contraindication) and place leg in dependent position and keep warm.
- Duplex or CT angiography - endovascular recanalization (PTA or stent, thrombectomy).
- Closure device-related stenosis or occlusion: re-access proximally, PTA or stent.
- Distal embolism: selective aspiration or thrombectomy.
- Surgery (thromboendarterectomy, bypass) only if endovascular failure.


Do and don't - short checklist

Do • Alert early, do not wait and see. • Prompt imaging (CT or CT angiography) if retroperitoneal bleeding is suspected. • Endovascular as first line, surgery as second line after consultation. • Actively apply anticoagulation or antidote pathways.

Don't • No forced compression if the source is unclear - diagnostics first. • No delayed escalation despite hemoglobin drop or hemodynamic changes. • Do not stop essential antiplatelet therapy without consultation with neurointervention (stent - risk of intracranial occlusion).

Simplified modified Rankin

Bruno et al. Stroke 2011



Notes

www.strokecenter.ch

2026

By making use of the "Stroke Guidelines of the Bern Stroke Network, created by Inselspital, Bern University Hospital (hereafter referred to as "Inselspital"), the user accepts the following conditions and their legally binding effects.

User conditions

This application serves exclusively as scientific information for the treatment of cerebrovascular diseases at the Inselspital. It is not intended as an action guideline for health experts or third parties. The information provided in this application is neither suited for nor designated for the following: dictation or replacement of individual diagnostic and/or therapeutic decisions, or calculation of personalized data or use of processed data for personal treatment decisions. All medical decisions regarding diagnosis and treatment of patients reside solely with the responsible physician.

Disclaimer

The Inselspital has endeavored to ensure the accuracy and completeness of the information published in this application. The contents of this information were assembled with great care and correspond to the medical science and technology as of the date of publication. Furthermore, the Inselspital endeavors to ensure that the application functions correctly. However, the Inselspital cannot guarantee accuracy, completeness, and up-to-date accuracy of the information or of the uninterrupted functioning of the application.

Neither the Inselspital, nor other parties involved in the development of this application, carry a warranty for damages or injuries resulting from the use or impossibility of use of this application. The user accesses the contents at his/her own risk. After examination and consideration of the provided information, the user is obliged to act on these guidelines at his/her own responsibility.

Copyright

Downloading, saving and printing of contents, including the figures, is permitted if the source is cited. Drawings from Anja Giger, may be freely distributed with appropriate source citation with Creative- Commons-Licence Naming - Non commercial - Distribution under the same conditions, , 4.0 International Lizenz (CC BY-NC-SA). <https://creativecommons.org>. The Inselspital logo that appears in the application is protected and may not be used in any way.

NIHSS (see pp. 62 to 63 for details)

Item	Rating	Item	Rating
LOC	0 Alert 1 not alert 2 Sopor 3 Coma	RIGHT and LEFT Motor Legs Amputation or stiffening= 0, Coma=4	0 no drift 1 drift (< 5sec) 2 active movement against gravity 3 no active movement against gravity 4 no movement at all
Orientation Anarthria, Intubation=1, Coma=2	Ask months and age 0 both correct 1 one correct 2 none correct	Limb ataxia with coma, aphasia, plegia=0	0 missing 1 one extremity 2 two extremities
Commands	Close eyes, squeeze hand 0 both correct 1 one correct 2 none correct	Sensitivity bilateral=2, Coma=2 if no reaction to pain, with aphasia rather 1	0 Normal 1 Light 2 Heavy to complete
Oculomotor Insufficient cooperation=1, Coma=2	0 normal 1 partial palsy 2 forced deviation	Aphasia Let intubated (wake) patients write, coma=3	0 Normal 1 light to moderate 2 Severe 3 Mute, global
Visual field Not assessable=0, Neglect=1, Coma=3, rate if aphasia blink to frightening movement	0 no restriction 1 partial hemianopsia 2 complete hemianopsia 3 bilateral hemianopsia	Dysarthria Coma=2	0 normal 1 mild to moderate 2 Severe (anarthric or incomprehensible)
Facial palsy Grimaces at pain stimulus, coma=3	0 normal 1 low 2 partial 3 complete	Neglect Not assessable=0, coma=2	0 None 1 Extinction 2 Severe neglect >1 quality
RIGHT and LEFT motor function arms with amputation or joint fusion=0, coma=4	0 no drift 1 drift (< 10 sec) 2 active movement against gravity 3 no active movement against gravity 4 no movement at all		

GCS	
Eyes	1 No reaction; 2 to pain; 3 to speech; 4 spontaneously open
Verbal	1 No reaction; 2 incomprehensible; 3 random speech; 4 disorientated, answers questions; 5 oriented and answers
Motor	1 No reaction; 2 extension; 3 flexion; 4 defense-Flexion; 5 localizes pain; 6 obey commands